


5th Inflammatory Skin Disease Summit

The Translational Revolution

November 15-18, 2023

Aula der Wissenschaften, Vienna, Austria



FINAL PROGRAM



Table of Contents

WELCOMING WORDS	2
GENERAL INFORMATION	3
CONFERENCE VENUE	4
REGISTRATION	8
OFFICIAL NETWORKING EVENTS	9
SCIENTIFIC PROGRAM INFORMATION	10
FACULTY SCIENTIFIC PROGRAMM	11
SCIENTIFIC PROGRAM	13
ACCEPTED ABSTRACTS	25
LATE-BREAKING ABSTRACTS	82
SPONSORS & EXHIBITORS	87
INDUSTRY SUPPORTED SESSIONS	88



Welcoming Words

Dear Friends and Colleagues,

We are delighted to welcome you to our “5th Inflammatory Skin Disease Summit: The Translational Revolution”, a unique and dynamic symposium, being held in Vienna, Austria, at the “Aula der Wissenschaften” on November 15-18, 2023.

Over the last few decades, biomedical research has unraveled a plethora of pathophysiological steps putatively important for human disease development. But it was only in the last few years that a broader translation from basic research efforts to clinical medicine has indeed occurred. This was largely made possible by the close cooperation of basic researchers with clinical investigators, aiming at the development of truly effective therapeutics. Inflammatory skin diseases such as psoriasis, atopic dermatitis, alopecia areata and vitiligo serve as an example of this successful bench-to-bedside approach. Currently, more and more therapies are approved as a result of this scientific approach, and many more are on their way.

Nevertheless, a stand-alone meeting in which inflammatory skin diseases and the translational revolution that we are currently experiencing take center stage has been lacking. After four very successful meetings in Vienna and in New York City in 2014, 2016, 2018 and 2021, we have again taken upon the task of organizing such an important in-person meeting, in order to continue this path of therapeutic revolution and extend to other inflammatory skin diseases. We want to discuss new concepts and new developments in the field of inflammatory skin diseases and to devise and explore new therapeutic strategies. For the last meetings, we had been able to attract true leaders in their fields, with more than 600 participants from all over the world at the last meetings in New York (2021) and Vienna (2018). We have now established this conference on an every two-year basis.

We are looking forward to welcoming you to ISDS 2023, in Vienna!

Emma Guttman, MD, PhD

Patrick M. Brunner, MD, MSc

James G. Krueger, MD, PhD

Georg Stingl, MD



General Information

ORGANIZING COMMITTEE

Emma Guttman, MD, PhD

Waldman Professor and System Chair
The Kimberly and Eric J. Waldman
Department of Dermatology
Director, Center of Excellence in Eczema
Director, Laboratory of Inflammatory Skin
Diseases
Icahn School of Medicine at Mount Sinai,
New York, USA

James G. Krueger, MD, PhD

Director, Milstein Medical Research
Program
Senior Attending Physician
D. Martin Carter Professor in Clinical
Investigation
Laboratory of Investigative Dermatology
The Rockefeller University New York,
NY, USA

Patrick M. Brunner, MD, MSc

Associate Professor
Director, Cutaneous Lymphoma Clinic
The Kimberly and Eric J. Waldman
Department of Dermatology
Icahn School of Medicine at Mount Sinai,
New York, USA

Georg Stingl, MD

Professor emeritus
Department of Dermatology
Medical University of Vienna, Austria

General Organization

SCIENTIFIC SECRETARIAT, REGISTRATION, HOTEL AND SPONSORSHIP INCL. COMMERCIAL EXHIBITION

Mondial Congress & Events

Operngasse 20b
1040 Vienna, Austria
Phone: +43 1 58804 - 159
Email: isds2023@mondial-congress.com




Conference Venue

Aula der Wissenschaften
Wollzeile 27a
A-1010 Vienna, Austria
www.aula-wien.at/en

WIFI

Free WIFI is available throughout the conference venue.

Network name: ISDS2023
No password required



Under the auspices of



How to get to the meeting

PUBLIC TRANSPORTATION

Public transport in Vienna is very well developed, clean and safe and moreover the fastest way of commuting in the city center. Therefore we recommend to go by underground or tram.

- Underground U3 – Station ‘Stubentor’ (3 min)
- Underground U1 or U3 – Station ‘Stephansplatz’ (7 min)
- Underground U1 or U4 – Station ‘Schwedenplatz’ (7 min)
- Tram no. 2 – Station ‘Stubentor’ (3 min)

More information about public transport on www.wienerlinien.at.

PARKING


Since parking near the conference venue is generally short-term, it is highly advisable to use a public parking garage in the area.

- Garage Cobdengasse Cobdengasse 2, 1010 Vienna
- Georg Cochplatz Tiefgarage Georg Cochplatz 4, 1010 Vienna
- Parkhaus City Stephansplatz/Schulerstraße, 1010 Vienna

Conference Venue

BASEMENT - CLOACKROOM & LAVATORIES

GROUND FLOOR




FIRST FLOOR



Conference Venue

SECOND FLOOR



Registration

The registration area is located in the entry hall on the ground floor. Our registration team will be pleased to help you with any inquiries.

REGISTRATION DESK HOURS

- Tuesday, November 14, 2023 16:30 – 19:30
- Wednesday, November 15, 2023 07:00 – 19:30
- Thursday, November 16, 2023 07:30 – 18:00
- Friday, November 17, 2023 07:30 – 19:00
- Saturday, November 18, 2023 07:30 – 15:00

ONSITE REGISTRATION FEES

Registration Fee	EUR 650
Students* / Residents & Fellows**	EUR 350

* *Student Fee: Students need to provide a copy of their valid Student ID when registering, otherwise the student registration will not be accepted.*

** *Resident: In order to verify your status as a resident, a written confirmation from your hospital/ institution will be required, otherwise regular admission will apply.*

THE REGISTRATION FEE INCLUDES:

- Participation in the scientific program (incl. industry sessions)
- Conference materials
- Coffee Breaks
- Attendance at Welcome Reception & Poster Viewing
- Admission to the exhibition areas

PAYMENT DETAILS

Please note that all onsite payments need to be made by credit card (Visa, MasterCard, American Express, Diners will be accepted) or in cash in EUR (€) only. We cannot accept traveller's checks, other credit cards, Euro checks or other currencies.

CME ACCREDITATION

The 5th Inflammatory Skin Disease Summit has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) with **26 European CME credits**. Each medical specialist should claim only those hours of credit that they actually spent in the educational activity.



Official Networking Events

WELCOME RECEPTION & POSTER VIEWING

Date and Time: Wednesday, November 15, 2023 | 19:00-22:00

Location: Conference Venue – Aula der Wissenschaften
Poster Areas (Ground Floor & First Floor)

OFFICIAL NETWORKING EVENING

Date and Time: Thursday, November 16, 2023 | 19:30

Location: Heuriger Fuhrgassl-Huber, Neustift am Walde 68, 1190 Vienna

Bus Transfer will be provided.

Departure 18:45 & 19:15 at Weiskirchnerstraße 3, 1010 Vienna
(between MAK & the Stadtpark)

Admission to the Official Networking Evening is € 50 per person.

Tickets are limited and available at own expense through the ISDS online registration or at the registration desk onsite at the conference.

COFFEE BREAKS

Coffee breaks with coffee, water and small snacks will be provided during official coffee breaks in the official catering areas located on the ground floor and first floor.

BREAKFAST, LUNCH & DINNER

Will be provided at selected Industry Symposia.

Scientific Program Information

SPEAKERS' LOUNGE

The Speakers' Lounge is located on the second floor, next to the lecture hall.

The hours of operation are as follows:

- Wednesday, November 15, 2023 07:00-18:00
- Thursday, November 16, 2023 07:30-17:30
- Friday, November 17, 2023 07:30-18:00
- Saturday, November 18, 2023 07:30-14:00

PRESENTATION GUIDELINES

- Speakers are required to provide their USB drives containing their PowerPoint presentation (format 16:9) to the AV technician in the Speaker's Lounge on the second floor at least one hour prior to the start of the respective session. For sessions starting in the morning, the PowerPoint should be delivered the previous day. We strongly encourage you not to bring your own laptop. Presentations should be on USB.
- Please locate the session prior to your presentation time and be there at least 15 minutes before the start of the session.
- Speakers can view/check their PowerPoint presentations at the Speakers' Lounge

SESSION CHAIRPERSON GUIDELINES

Please locate the session room in due time and be there at least 15 minutes prior to the start of the session. We may remind you that speakers need to strictly adhere to the time schedule.

POSTERS

The poster areas are located on two floors. Each poster will be displayed for the entire duration of the summit. Posters have to be mounted until Wednesday, November 15, before 10 am. Please **attach the poster to the board with the corresponding poster placement number** and remove it on Saturday, November 18, 2023, until 15:00.

ABSTRACT BOOK

The abstracts are published in a supplement of the Journal of Investigative Dermatology. The abstract book is available for download on the ISDS Conference website.



Faculty Scientific Programm

SPEAKERS

Patrick M. Brunner, New York, USA
Rachael Clark, Boston, USA
Richard Flavell, New Haven, USA
Massimo Gadina, Bethesda, USA
Michel Gilliet, Lausanne, Switzerland
Johann Gudjonsson, Ann Arbor, USA
Emma Guttman, New York, USA
Muzlifah Haniffa, Newcastle, UK
John Harris, Worcester, USA
Alan Irvine, Dublin, Ireland
Kenji Kabashima, Kyoto, Japan
Dan Kaplan, Pittsburgh, USA
Brian Kim, New York, USA
Heidi Kong, Bethesda, USA
James Krueger, New York, USA
Bart Lambrecht, Ghent, Belgium
Marcus Maurer, Berlin, Germany
Johannes U. Mayer, Marburg, Germany
Joseph Merola, Boston, USA
Ralf Paus, Miami, USA
Aimee Payne, Philadelphia, USA
Kristian Reich, Hamburg, Germany
Eli Sprecher, Tel Aviv, Israel
Georg Stary, Vienna, Austria
Georg Stingl, Vienna, Austria
Philipp Tschandl, Vienna, Austria
Nicole L. Ward, Nashville, USA

SYMPOSIUM ON MALIGNANT SKIN INFLAMMATION

Oleg Akilov, Pittsburgh, USA
Martine Bagot, Paris, France
Patrick M. Brunner, New York, USA
Rachael Clark, Boston, USA
Gabor Dobos, Berlin, Germany
Shamir Geller, New York, USA
Larisa Geskin, New York, USA
Michael Girardi, New Haven, USA
Emmanuella Guenova, Lausanne, Switzerland
Muzlifah Haniffa, Newcastle, UK
Emmilia Hodak, Tel Aviv, Israel
Annemieke de Jong, New York, USA
Sergei Koralov, New York, USA
Adèle de Masson, Paris, France
Niels Ødum, Copenhagen, Denmark
Christiane Querfeld, Duarte, USA
Peter Wolf, Graz, Austria

PRIZE COMMITTEE

Paul Bergstresser, Dallas, USA
Liv Eidsmo, Copenhagen, Denmark
Thomas Schwarz, Kiel, Germany

SESSION CHAIRS

Aviv Barzilai, Tel Aviv, Israel
 Lisa Beck, Rochester, USA
 Paul Bergstresser, Dallas, USA
 Robert Bissonnette, Montreal, Canada
 Marie-Charlotte Brügggen, Zurich, Switzerland
 Enno Christophers, Kiel, Germany
 Liv Eidsmo, Copenhagen, Denmark
 Larisa Geskin, New York, USA
 Johannes Griss, Vienna, Austria
 Emmanuella Guenova, Lausanne, Switzerland
 Claudia Günther, Dresden, Germany
 Jan Gutermuth, Brussels, Belgium
 Wolfram Hötzenecker, Linz, Austria
 Constanze Jonak, Vienna, Austria
 Leon Kircik, New York, USA
 Thomas Luger, Münster, Germany
 Evangelina Papadavid, Athens, Greece
 Yael Renert-Yuval, Tel Aviv, Israel
 Christoph Schlapbach, Bern, Switzerland
 Matthias Schmutz, Innsbruck, Austria
 Agatha Schwarz, Kiel, Germany
 Franz Trautinger, St. Pölten, Austria
 Erwin Tschachler, Vienna, Austria
 Wolfgang Weninger, Vienna, Austria
 Peter Wolf, Graz, Austria

ORAL ABSTRACT PRESENTERS

Constance Alvarez-Duchesne, Aulnay-Sous-Bois, France
 Christine Bangert, Vienna, Austria
 Jonathan Bar, New York, USA
 Patrick M. Brunner, New York, USA
 Ian M. Catlett, Princeton Pike, USA
 Roxane Cuzin, Lyon, France
 Ester Del Duca, New York, USA
 Jeff Gehlhausen, New Haven, USA
 Amos Gilhar, Haifa, Israel
 Iris K. Gratz, Salzburg, Austria
 Sophie Guenin, New York, USA
 Emma Guttman-Yassky, New York, USA
 Hans E. Hofland, Palo Alto, USA
 John Kelly, Colledgeville, USA
 Hyun Je Kim, Seoul, South Korea
 Madeline Kim, New York, USA
 Brian Kirby, Dublin, Ireland
 Lisa Kleissl, Vienna, Austria
 Catherine Lu, New York, USA
 Fabian Luther, Bern, Switzerland
 Britta Martel, Ballerup, Denmark
 Kristina Navrazhina, New York, USA
 Anna Redl, Vienna, Austria
 Stefanie Schärli, Bern, Switzerland
 Shany Sherman, Worcester, USA
 Susan Smith, Wilmington, USA
 Karoline Strobl, Vienna, Austria
 Stephan Traidl, Hannover, Germany
 Wendell Valdecantos, Cambridge, USA
 Matthew Vesely, New Haven, USA
 Marc Vocanson, Lyon, France
 Yiyi Wang, Chengdu, China
 Wenning Zheng, Copenhagen, Denmark



Scientific Program

WEDNESDAY, NOVEMBER 15, 2023

PRE-MEETING SYMPOSIA

SYMPOSIUM ON MALIGNANT SKIN INFLAMMATION

Organizing committee: *Patrick Brunner, New York, USA*
Constanze Jonak, Vienna, Austria
Larisa Geskin, New York, USA
Emmanuella Guenova, Lausanne, Switzerland

8.00 am-8.10 am Welcome address
Organizing committee

MALIGNANT INFLAMMATION - ROLE OF INFECTIONS AND ENVIRONMENTAL DRIVERS

Chairs: *Patrick Brunner, New York, USA*
Constanze Jonak, Vienna, Austria

8.10 am-8.30 am Keynote lecture: Bacteria fuel malignant inflammation and disease activity in CTCL
Niels Ødum, Copenhagen, Denmark

8.30 am-8.50 am Microbial triggers and clonal evolution in CTCL pathogenesis
Sergei Koralov, New York, USA

8.50 am-9.10 am Chronic T cell activation by CD1a and Staphylococcal lipids
Annemieke de Jong, New York, USA

9.10 am-9.30 am AhR signaling drives defective type I IFN signaling in mycosis fungoides
Rachael Clark, Boston, USA

9.30 am-9.50 am Infectious and environmental drivers of CTCL
Larisa Geskin, New York, USA

10.00 am- 10.30 am COFFEE BREAK

ROLE OF THE MICROENVIRONMENT

Chairs: Evangelina Papadavid, Athens, Greece
Larisa Geskin, New York, USA

10.30 am - 10.50 am The micromilieu in CTCL: From inflammation over tumor progress to antitumoral response
Gabor Dobos, Berlin, Germany

10.50 am - 11.10 am Targeting immunosuppressive macrophages in the tumor microenvironment of CTCL
Christiane Querfeld, Duarte, USA

11.10 am - 11.30 am The role of cancer-associated fibroblasts in MF
Emmilia Hodak, Tel Aviv, Israel

11.30 am - 11.50 am ADCC in lymphoma treatment - A spotlight on NK cells?
Emmanuella Guenova, Lausanne, Switzerland

12.00 pm - 1.00 pm SPONSORED LUNCH SYMPOSIUM
(Details can be found on page 88 ff.)

PATHOGENESIS AND ITS TRANSLATION

Chairs: Emmanuella Guenova, Lausanne, Switzerland
Johannes Griss, Vienna, Austria

1.00 pm - 1.20 pm Towards a better understanding of the CTCL cellular and molecular landscape
Muzlifah Haniffa, Newcastle, UK

1.20 pm - 1.40 pm Insights into pathogenesis and translational strategies for CTCL
Michael Girardi, New Haven, USA

1.40 pm - 2.00 pm An individualized approach to therapy of advanced MF in the era of personalized medicine
Oleg Akilov, Pittsburgh, USA

2.00 pm - 2.20 pm Indolent vs. aggressive disease
Patrick M. Brunner, New York, USA

2.20 pm - 2.40 pm COFFEE BREAK



PATHOGENESIS BASED TREATMENT STRATEGIES

Chairs:

Franz Trautinger, St. Pölten, Austria

Christoph Schlapbach, Bern, Switzerland

2.40 pm - 3.00 pm

CTCL: unraveling the mechanisms of long-term disease control

Adèle de Masson, Paris, France

3.00 pm - 3.20 pm

New treatment targets

Martine Bagot, Paris, France

3.20 pm - 3.40 pm

Therapeutic mechanisms in CTCL: Lessons learnt from photo(chemo)therapy

Peter Wolf, Graz, Austria

3.40 pm - 4.00 pm

The association of CTCL with inflammatory skin disorders and its treatments - True causality or misdiagnosis?

Shamir Geller, New York, USA

4.00 pm - 4.15 pm

Concluding remarks

IEC PRE-MEETING

1.00 pm - 4.00 pm

Research Techniques in Atopic Dermatitis

(Registration via IEC website required)

International Eczema Council

Venue: Festive Hall of the Austrian Academy of Science

(Dr. Ignaz Seipel-Platz 2, 1010 Vienna, Austria)

ISDS 2023 CONFERENCE OPENING

4.30 pm - 4.40 pm

Welcome Address
Organizing Committee

Welcome Words from the president of the Austrian Academy of Sciences
Heinz Faßmann

4.40 pm - 5.00 pm

Setting the Stage
Georg Stingl, Vienna, Austria

5.00 pm - 5.30 pm

Keynote lecture
"Immune system-driven skin fibrosis"
Richard Flavell, New Haven, USA

5.30 pm - 6.00 pm

Type 2 immunity across diseases
Bart Lambrecht, Ghent, Belgium

6.00 pm - 7.00 pm

Oral presentations from selected abstracts

207 Spatial proteomic and transcriptomic profiling of lichen planus reveals a unique inflammatory architecture
Matthew Vesely, New Haven, USA

56 Targeting the IL-15 signaling pathway prevents the formation of cutaneous TRM and limits flare-ups of allergic contact dermatitis
Roxane Cuzin, Lyon, France

168 Effectivity of mTOR inhibition in cutaneous sarcoidosis
Anna Redl, Vienna, Austria

142 Bidirectional TGF-beta signaling between CD8+ T cells and melanocytes determines melanocyte death in vitiligo, rescued by small-molecule receptor blocker
Shany Sherman, Worcester, USA

260 The Phase 2 MIRA trial of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with active, moderate-to-severe hidradenitis suppurativa (HS): Week 12 results
Brian Kirby, Dublin, Ireland

7.00PM - 10.00PM

Reception and poster viewing



THURSDAY, NOVEMBER 16, 2023

8.00 am - 9.30 am Sponsored Breakfast Symposium
(Details can be found on page 88 ff.)

9.30 am - 9.45 am BREAK

Morning lectures

Chairs: Christoph Schlapbach (Bern, Switzerland)
Agatha Schwarz (Kiel, Germany)

9.45 am - 10.15 am Innate immunity in the skin
Michel Gilliet, Lausanne, Switzerland

10.15 am - 10.45 am The microbiome in inflammatory skin diseases
Heidi Kong, Bethesda, USA

10.45 am - 11.15 am Developing a human skin cell atlas
Muzlifah Haniffa, Newcastle, UK

11.15 am - 11.45 am Oral presentations from selected abstracts

150 Skin CD69+CD62L+ TRM, a subset with renewal capacity gives rise to CD103+CD49a+ TRM
Wenning Zheng, Copenhagen, Denmark

82 IL-9 sensitizes human pathogenic Th2 cells to pro-inflammatory IL-18 signals in atopic dermatitis
Stefanie Schärli, Bern, Switzerland

11.45 am - 12.00 pm BREAK

12.00 pm - 1.30 pm Sponsored Lunch Symposium
(Details can be found on page 88 ff.)

1.30 pm - 1.45 pm BREAK

Afternoon lectures I

Chairs: Lisa Beck (Rochester, USA)
Leon Kircik (New York, USA)

1.45 pm - 2.15 pm Mitochondrial ROS and cytoplasmic nucleic acid sensing set the inflammatory tone in human skin
Rachael Clark, Boston, USA

- 2.15 pm - 2.45 pm** Cutaneous T cell compartments in health and immunodeficiency
Georg Stry, Vienna, Austria
- 2.45 pm - 3.15 pm** Chronic inflammation - what we learn from cutaneous lymphomas
Patrick M. Brunner, New York, USA
- 3.15 pm - 3.45 pm** Oral presentations from selected abstracts
- 196 Squamous Cell Carcinoma in patients with Recessive Dystrophic Epidermolysis Bullosa is associated with dysregulated T cell function
Iris K. Gratz, Salzburg, Austria
- 61 Influence of dupilumab on HSV-specific immune response in atopic dermatitis
Stephan Traidl, Hannover, Germany
- 3.45 pm - 4.15 pm** COFFEE BREAK
- Afternoon lectures II**
Chairs: *Liv Eidsmo (Copenhagen, Denmark)*
Claudia Günther (Dresden, Germany)
- 4.15 pm - 4.45 pm** Dissecting the role of IL-13 in health and disease
Johannes U. Mayer, Marburg, Germany
- 4.45 pm - 5.15 pm** Janus kinases in inflammation
Massimo Gadina, Bethesda, USA
- 5.15 pm - 5.45 pm** Psoriasis
Johann Gudjonsson, Ann Arbor, USA
- 5.45 pm - 6.15 pm** Newly identification of a CXCR6+ pathogenic skin-resident CD4+ T cell subset in a mouse model of allergic dermatitis that requires CXCL16 for its maintenance
Kenji Kabashima, Kyoto, Japan
- 7.30 pm - 11.00 pm** Conference Networking Event
Bus transfer - 06.45 pm & 9.15 pm from Weiskirchnerstraße 3, 1010 Vienna



FRIDAY, NOVEMBER 17, 2023

Morning lectures I*Chairs:**Robert Bissonnette (Montreal, Canada)**Peter Wolf (Graz, Austria)***8.00 am - 9.30 am**

Oral presentations from selected abstracts

105 AhR agonism by tapinarof regulates TH2 and TH17 cell function in human skin*Fabian Luther, Bern, Switzerland***194** Effect of Ruxolitinib Cream on Biomarkers of Atopic Dermatitis*Susan Smith, Wilmington, USA***146** Treatment with the oral CCR4 antagonist RPT193 results in meaningful changes in cutaneous biomarkers detected by transcriptomic profiling of tape strips*Ester Del Duca, New York, USA***11** Spesolimab Use in Treatment of Severe Pyoderma Gangrenosum*Sophie Guenin, New York, USA***227** Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a Phase 2b trial (STREAM-AD)*Wendell Valdecantos, Cambridge, USA***68** EVO756 is a novel MRGPRX2 antagonist that potentially inhibits human mast cell degranulation in response to multiple agonists - potential treatment for CSU and beyond*Hans E Hofland, Palo Alto, USA***190** Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis*Emma Guttman-Yassky, New York, USA***9.30 am - 9.45 am**

BREAK

Morning lectures II

Chairs: Marie-Charlotte Brüggem (Zurich, Switzerland)
Erwin Tschachler (Vienna, Austria)

9.45 am - 10.15 am Neuronal immunology interactions
Dan Kaplan, Pittsburgh, USA

10.15 am - 10.45 am Itch and neuroinflammation
Brian Kim, New York, USA

10.45 am - 11.15 am "Of mice and men" - A Tale of Inflammatory Skin Diseases
Nicole Ward, Nashville, USA

11.15 am - 11.45 am Oral presentations from selected abstracts

216 Human epidermal Langerhans cells emigrate and induce a tolerogenic immune response in response to tick feeding and tick-borne pathogens
Lisa Kleissl, Vienna, Austria

220 Detection of skin allergy biomarkers for point-of-care diagnosis of contact dermatitis
Marine-Alexia Lefevre, Bron, France

11.45 am - 12.00 pm BREAK

12.00 pm - 01.30 pm Sponsored Lunch Symposium
(Details can be found on page 88 ff.)

1.30 pm - 1.45 pm BREAK

Afternoon lectures I

Chairs: Jan Gutermuth (Brussels, Belgium)
Matthias Schmuth (Innsbruck, Austria)

1.45 pm - 2.15 pm Advances in atopic dermatitis
Alan Irvine, Dublin, Ireland

2.15 pm - 2.45 pm Alopecia areata
Ralf Paus, Miami, USA

2.45 pm - 3.15 pm Atopic dermatitis & alopecia areata: Common mechanisms and targets
Emma Guttman, New York, USA



3.15 pm - 3.45 pm

Oral presentations from selected abstracts

153 Effectiveness of OR-101, a Next Generation Highly Selective JAK3 Inhibitor, in a Humanized Murine Model of Alopecia Areata*Marta Bertolini, Münster, Germany***231 Non-lesional type 2 and type 17/22 immune activation precedes lesional type 1-associated inflammation in skin of vitiligo patients***Patrick M. Brunner, New York, USA***3.45 pm - 4.15 pm**

COFFEE BREAK

Afternoon lectures II

Chairs:

*Aviv Barzilai (Tel Aviv, Israel)**Enno Christophers (Kiel, Germany)***4.15 pm - 4.45 pm**

Oral presentations from selected abstracts

226 Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells*Christine Bangert, Vienna, Austria***148 Tape strips detect molecular alterations and cutaneous biomarkers in hidradenitis suppurativa skin***Kristina Navrazhina, New York, USA***4.45 pm - 5.15 pm****Hidradenitis suppurativa***James G. Krueger, New York, USA***5.15 pm - 5.45 pm****Emerging opportunities in vitiligo***John Harris, Worcester, USA*

5.45 pm - 06.45 pm Oral presentations from selected abstracts

203 Immune-mesenchymal crosstalk contribute to the expansion of autoreactive plasma cells in the tertiary lymphoid structures in hidradenitis suppurativa

Catherine Lu, New York, USA

205 Tape Strip Genomic Profiling of Lesional and Nonlesional Atopic Dermatitis Skin Identifies Early and Progressive Normalization Following Treatment With Abrocitinib

Madeline Kim, New York, USA

171 Deciphering dysfunctional regulatory T cells in atopic dermatitis

Hyun Je Kim, Seoul, South Korea

277 Efficacy, Safety, and Tolerability of GSK1070806, an Anti-IL-18 Monoclonal Antibody, in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study

John Kelly, Collegeville, USA

06.45 pm - 7.00 pm BREAK

7.00 pm - 8.30 pm Sponsored Dinner Symposium

(Details can be found on page 88 ff.)



SATURDAY, NOVEMBER 18, 2023

Morning lectures I

Chairs: Thomas Luger (Münster, Germany)
 Wolfram Hötzenecker (Linz, Austria)

8.00 am - 9.30 am Oral presentations from selected abstracts

62 Single cell transcriptome revealed the role of CCL19+ inflammatory epithelial cells in pemphigus

Yiyi Wang, Chengdu, China

140 Chronic hand eczema shares a common molecular signature regardless of atopic dermatitis status

Jonathan Bar, New York, USA

215 Cutaneous lupus single cell analyses reveal critical type I interferon mediated reprogramming of skin stroma

Jeff Gehlhausen, New Haven, USA

27 Preclinical Ex Vivo and In Vivo Evidence Supporting Selective Inhibition of Tyrosine Kinase 2-Dependent, IL-12-Mediated Signaling as a Novel Pharmacological Strategy for Alopecia Areata Management

Ian M. Catlett, Princeton Pike, USA

54 A Chronic Inflammatory Environment Revealed In Age Spots From Both European And Asian Volunteers

C. Alvarez-Duchesne, Aulnay-Sous-Bois, France

134 Clinical response to IL-22RA1 blockade is associated with reduction of systemic inflammation

Britta Martel, Ballerup, Denmark

9.30 am - 9.45 am BREAK

Morning lectures II

Chairs: Yael Renert-Yuval (Tel Aviv, Israel)
Wolfgang Weninger (Vienna, Austria)

9.45 am - 10.15 am Academic / industry collaboration and perspectives
Kristian Reich, Hamburg, Germany

10.15 am - 10.45 am The Past, Present, and Future of Cell Therapies for Autoimmunity
Aimee Payne, Philadelphia, USA

10.45 am - 11.15 am Lupus: New Developments
Joseph Merola, Boston, USA

11.15 am - 11.45 am The role of the target tissue in skin autoimmunity: pemphigus as a case study
Eli Sprecher, Tel Aviv, Israel

11.45 am - 12.00 pm Oral presentations from selected abstracts
59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
Karoline Strobl, Vienna, Austria

12.00 pm - 12.15 pm BREAK

12.15 pm - 1.45 pm Sponsored Lunch Symposium
(Details can be found on page 88 ff.)

1.45 pm - 2.00 pm BREAK

Afternoon lectures

Chairs: Johannes Griss (Vienna, Austria)
Paul Bergstresser (Dallas, USA)

2.00 pm - 2.30 pm Artificial Intelligence in Dermatology
Philipp Tschandl, Vienna, Austria

2.30 pm - 3.00 pm Urticaria
Marcus Maurer, Berlin, Germany

3.00 pm Closing & Farewell

3.00 pm - 3.30 pm COFFEE BREAK

3.30 pm - 6.00 pm Industry Satellite Event
(Details can be found on page 88 ff.)



Accepted Abstracts

All abstracts will be published in a supplement of the Journal of Investigative Dermatology.



- 1 Pruritus characteristics in patients with plaque psoriasis**
 Jisang Yun^{1,3}, Kihyuk Shin^{1,3}, Hyun-Chang Ko^{1,3}, Moon-Bum Kim^{1,2},
Byungsoo Kim^{1,2}
¹*Department of Dermatology, School of Medicine, Pusan National University, Busan, South Korea*
²*Department of Dermatology, Pusan National University Hospital, Busan, South Korea*
³*Department Of Dermatology, Pusan National University Yangsan Hospital, Yangsan, South Korea*
- 2 A case of linear cutaneous lupus erythematosus**
Huimin Meng¹
¹*成都市第二人民医院, Chengdu, 中国*
- 3 Hand-foot-vulva pustule After COVID-19 inactive vaccine**
Yihang Xie¹, Bin Yin¹
¹*Chengdu Second People's Hospital, Qingyun Street, Chengdu, China*
- 4 Cytokine gene polymorphisms and their relation with NFκB Expression and Histopathological Features in Psoriasis**
Debdeep Mitra¹
¹*Command Hospital Air Force Bangalore, Bangalore, India*
- 5 A Case of Bullous Pemphigoid Associated with Membranous Nephropathy**
 Liming Xiang¹, Bin Yin¹
¹*Chengdu Second People's Hospital, Chengdu, China*
- 6 A patient with leathery firm ulcerative papules with pruritus**
Liming Xiang¹, Peimei Zhou¹
¹*Chengdu Second People's Hospital, Chengdu, China*
- 7 The mechanism of YKL-40 in enhancing the vascular permeability induced by Histamine**
Peimei Zhou¹
¹*Chengdu Second People's Hospital, Chengdu, China*

- 8 **Investigating the Effects of an Omega-3 rich Brown Seaweed Extract on Atopic Dermatitis in a Keratinocytes Raft Model**
Jamie Mei Lin Kok^{1,2}, Georgina C Dowd³, Jaydee D Cabral², Lyn Wise²
¹*Queensland University Of Technology, Brisbane, Australia*
²*Otago University, Dunedin, New Zealand*
³*The New Zealand Institute for Plant & Food Research Limited, Nelson, New Zealand*
- 9 **Burden, pattern, associated factors and impact on quality of life of dermatological disorders among the elderly in Ilala Municipality, Dar es Salaam.**
Md Uwesu Muki¹, Uwesu Muki¹, Grace Shayo¹, Eliaichi Minja Muhammad Bakari¹, Ashura Kazema¹
¹*Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar-es-salaam, Tanzania*
- 10 **(Neutrophil Extracellular Traps) NET-worth of Neutrophils in Psoriasis**
Debdeep Mitra¹
¹*Command Hospital Air Force Bangalore, Bangalore, India*
- 11 **Spesolimab Use in Treatment of Severe Pyoderma Gangrenosum**
Sophie Guenin¹, Saakshi Khattri¹, Mark Lebwohl¹
¹*Mount Sinai Dermatology, New York, United States*
- 12 **Safety and Efficacy of Dual TYK2 Inhibitor and Biologic Therapy**
Sophie Guenin¹, Elizabeth Andrews¹, Mark Lebwohl¹
¹*Mount Sinai Dermatology, New York, United States*
- 13 **UV filters regulate epidermal differentiation and psoriasis-like inflammation in human keratinocytes**
Yu-Chun Huang¹, Kai-Yen Chang¹, Chao-Hsun Yang¹
¹*Department of Cosmetic Science, Providence University, Taichung, Taiwan*
- 14 **Evaluation of The Serum 25- Hydroxyvitamin D Levels and Body Mass Index in Patients with Familial and Non-familial Psoriasis and Their Association with Disease Severity**
Muhsin Al-dhalimi¹
¹*University Of Kufa, Najaf, Iraq*
- 15 **Evaluation of Several Hematological and Inflammatory Parameters in Patients with Alopecia Areata and Their Correlation with Disease Severity**
Muhsin Al-dhalimi
¹*University Of Kufa, Najaf, Iraq*



- 16** THE EARLY TRANSCRIPTIONAL RESPONSE OF FIBROBLASTS TO NON-HEALING WOUND EXUDATES REVEALS ROLES FOR INFLAMMATION AND UNFOLDED PROTEIN RESPONSE IN THE PATHOLOGY OF CHRONIC WOUNDS.
Gabriela Cabral¹, Petra Dörfler¹, Nicole Schöfmann¹, Anton Stütz¹, Barbara Wolff-Winiski¹
¹*Akribes Biomedical, Vienna, Austria*
- 17** New-onset bullous pemphigoid after SARS-CoV-2 infection
Sijie Zhai¹
¹*Chengdu Second People's Hospital, Chengdu, China*
- 18** Combination Treatment with Adipose Stem Cell Exosomes (ASCE) and Fractional CO₂ Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study
Byong Seung Cho¹
¹*Exocobio Inc., Osong, South Korea*
- 19** Adipose Stem Cell Exosome (ASCE): Next Generation Regenerative Therapeutics for Atopic Dermatitis
Byong Seung Cho¹
¹*Exocobio Inc., Osong, South Korea*
- 20** Exosomes derived from adipose tissue-derived mesenchymal stem cells (ASCE) for the treatment of dupilumab-related facial redness in patients with atopic dermatitis
Byong Seung Cho¹
¹*Exocobio Inc., Osong, South Korea*
- 21** Adipose Stem Cell Exosome (ASCE): Next Generation Regenerative Aesthetics & Therapeutics for Scalp & Hair
Byong Seung Cho¹
¹*Exocobio Inc., Osong, South Korea*
- 22** Biological Functions of Exosome-like Nanoparticles Isolated from Rose (*Rosa damascena*) Stem Cell Culture (RSCE)
Byong Seung Cho¹
¹*Exocobio Inc., Osong, South Korea*
- 23** Efficacy of combined treatment with adipose tissue stem cell exosomes (ASCE) and microneedling for facial skin aging: a 12-week prospective, randomized, split-face study
Byong Seung Cho¹
¹*Exocobio Inc., Osong, South Korea*

- 24** **ARQ-234: a high affinity CD200-Fc fusion protein for the treatment of atopic dermatitis**
Rebecca Ashfield¹, Joseph Sheridan², Jonathan Heal², David Berk¹, Patrick Burnett¹, David Blackburn³, Philip Huxley⁴
¹*Arcutis Biotherapeutics Inc, Westlake Village, United States*
²*RxCelerate (previously Prosarix Ltd), Babraham Research Campus, UK*
³*Institute of Medical Sciences, University of Aberdeen, Foresterhill, UK*
⁴*Ducentis Biotherapeutics Ltd, Bristol, UK*
- 25** **Dupilumab to Treat Drug Reaction with Eosinophilia and Systemic Symptoms**
Danielle Dubin¹, Daniel Yassky¹, Dina Poplasky¹, Jade Young¹, Kathryn Tan¹, Nicholas Gulati¹
¹*Icahn School Of Medicine At Mount Sinai, New York, United States*
- 26** **CHARACTERIZATION OF A MURINE MODEL OF AA INDUCED BY ADOPTIVE TRANSFER OF CULTURED LYMPH NODE CELLS**
Elena Calama¹, Jose Luis Gómez¹, Jose Luis Montero¹, Joan Mañé¹, Christos Kiourtis¹, Gloria Aniorte¹, Amadeu Gavalda¹
¹*Almirall SA, Sant Feliu De Llobregat, España*
- 27** **Preclinical Ex Vivo and In Vivo Evidence Supporting Selective Inhibition of Tyrosine Kinase 2-Dependent, IL-12-Mediated Signaling as a Novel Pharmacological Strategy for Alopecia Areata Management**
Janin Edelkamp¹, Thomas Rouille¹, Jin Hyang Kim², Aviad Keren³, Joana Viola-Söhnlein¹, Lu Gao², Alfredo Rossi⁴, Francisco Jimenez⁵, Amos Gilhar³, Ralf Paus⁶, Ian M. Catlett², Marta Bertolini¹
¹*Monasterium Laboratory GmbH, Münster, Germany*
²*Bristol Myers Squibb, Princeton Pike, United States*
³*Technion – Israel Institute of Technology, Haifa, Israel*
⁴*Sapienza University, Rome, Italy*
⁵*Meditekna Hair Transplant Clinic, Las Palmas de Gran Canaria, Spain*
⁶*University of Miami Miller School of Medicine, Miami, United States*
- 28** **A case of cutaneous nocardiosis misdiagnosed as tuberculosis**
Li Zhang¹, Bin Yin¹
¹*Chengdu Second People's Hospital, Chengdu, China*



- 29** **Epidemiology and Disease-Related Characteristics of Patients with Vitiligo: A Retrospective Real-World Data Analysis**
Yuval Ramot¹, Vered Rosenberg², Limei Zhou³, [Stephanie Harbers](#)⁴
¹*The Faculty of Medicine, Hebrew University of Jerusalem and Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel*
²*Kahn-Sagol-Maccabi Research and Innovation Institute, Maccabi Health Services, Tel Aviv, Israel*
³*AbbVie Inc., Toronto, Canada*
⁴*AbbVie Inc., Rungis, France*
- 30** **Demographic and Disease-Related Characteristics Among Patients with Moderate-to-Severe Vitiligo in Israel: A Retrospective Real-World Analysis**
Yuval Ramot¹, Vered Rosenberg², Limei Zhou³, Jolanta Zaikauskienė⁴, [Stephanie Harbers](#)⁵
¹*Department of Dermatology, Hebrew University of Jerusalem and Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel,*
²*Kahn-Sagol-Maccabi Research and Innovation Institute, Maccabi Health Services, Tel Aviv, Israel,*
³*AbbVie Inc., Toronto, Canada,*
⁴*AbbVie Baltic States, Vilnius, Lithuania,*
⁵*AbbVie Inc., Rungis, France*
- 31** **Evaluation of the correlation between serum levels of vitamin D and vitamin D receptor gene polymorphisms in vitiligo patients**
[Heba Mashaly](#)¹, Heba Gawdat¹, Khaldia Amr¹, Mahmoud Fawzy Abdel Hamid¹, Eman Shaalan¹
¹*Dermatology Department. Faculty Of Medicine, Cairo University, Cairo, Egypt*
- 32** **Estimation of Matrix Metalloproteinase-9 and Interleukin-17 Tissue Levels in Stable, Non-Segmental Vitiligo**
[Heba Mashaly](#)¹, Nahla Hunter¹, Olfat Shake¹r, Dina Dorgham¹, Sarah Ismail¹
¹*Dermatology Department. Faculty Of Medicine, Cairo University, Cairo, Egypt*
- 33** **Evaluation of carcinogenic risk of PUVA versus Re-PUVA in psoriatic patients**
[Heba Mashaly](#)¹, Maha Fathy¹, Olfat Shaker¹, Shaimaa Hamdy¹
¹*Dermatology Department. Faculty Of Medicine, Cairo University, Cairo, Egypt*
- 34** **The Risk of Infections with Janus Kinase Inhibitor Treatment for Atopic Dermatitis: A Systematic Review and Meta-Analysis**
Nawar Tarafdar¹, Muskaan Sachdeva², Natnaiel Dubale¹, Ciaran Smythe³, Yuliya Lytvyn², Khalad Maliyar², Jorge Georgakopoulos², Asfandyar Mufti², [Jensen Yeung](#)²
¹*Department of Medicine, Schulich School Of Medicine And Dentistry, London, Canada,*
²*Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada,*
³*Happy Valley, United States*

35 A Novel Therapeutic Approach using Taurodeoxycholate, a GPCR19R Agonist, for Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial with Identification of Predictive Biomarkers

Seung-Yong Seong^{1,2,3}, Aziz Ghaderpour^{1,2}, Hyoung Tae Kim¹, Kyu Han Kim⁴, Jung Im Na⁵, Chun Wook Park⁶, Seong Jun Seo⁷, Chang Ook Park⁸, Seung Hwa Lee¹, Ju Young Jeong¹, Jung Joong Hwang¹, Siwon Kim¹, Sun Ae Han¹

¹Shaperon Inc., Jagok-ro, Gangnam-gu, Seoul, South Korea

²Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea

³Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, South Korea

⁴Department of Dermatology, Veteran Health Service Medical Center, Seoul, Seoul, South Korea

⁵Department of Dermatology, Seoul National University Bundang Hospital, Seongnam, South Korea

⁶Department of Dermatology, Kangnam Sacred Heart Hospital, Hallym University, Seoul, South Korea

⁷Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea

⁸Department of Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea

36 Vitiligo in North Macedonia

Natasa Teovska Mitrevska¹

¹Remedika General Hospital, Skopje, North Macedonia

37 Switching to Systemic Janus Kinase Inhibitors Following Dupilumab Failure for Atopic Dermatitis: An Evidence-Based Review

Siddhartha Sood¹, Ahmed Bagit¹, Martin Heung², Khalad Maliyar³, Abraham Abduelmula³, Muskaan Sachdeva³, Jorge Georgakopoulos³, Asfandyar Mufti^{3,4}, Vimal Prajapati^{5,6,7,8,9,10}, Jensen Yeung^{3,4,10,11}

¹Temerty Faculty of Medicine, University of Toronto, Toronto, Canada

²Faculty of Health Sciences, McMaster University, Hamilton, Canada

³Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada

⁴Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Canada

⁵Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Canada

⁶Dermatology Research Institute, Calgary, Canada

⁷Skin Health & Wellness Centre, Calgary, Canada

⁸Section of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, Canada

⁹Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Canada

¹⁰Probit Medical Research, Waterloo, Canada

¹¹Department of Dermatology, Women's College Hospital, Toronto, Canada



- 38** **Epigenetic age acceleration and differential DNA methylation of novel biomarkers in a pediatric atopic dermatitis cohort**
Richie Jeremian^{1,2}, Alexandra Malinowski³, Edward Oh³, Melinda Gooderham⁴, Cathryn Sibbald⁵, Jensen Yeung⁶, Yuka Asai⁷, Denise Daley⁸, Carolyn Jack^{1,2}
¹Research Institute Of The McGill University Health Centre, Montréal, Canada
²McGill University Health Centre (MUHC) Center of Excellence for Atopic Dermatitis, Montréal, Canada
³Centre for Addiction and Mental Health, Toronto, Canada
⁴Skin Centre for Dermatology, Peterborough, Canada
⁵Division of Dermatology, Department of Paediatrics, University of Toronto, Toronto, Canada
⁶Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada
⁷Division of Dermatology, Department of Medicine, School of Medicine, Faculty of Health Sciences, Queen's University, Kingston, Canada
⁸Department of Medicine, The University of British Columbia Centre for Heart Lung Innovation, Vancouver, Canada
- 39** **Effectiveness, persistence of use, and safety of guselkumab in real clinical practice: a case series of 27 patients**
Nerea Mohino-Farré¹, Josep Pujol-Montcusi¹, Clara Martin-Callizo¹, Laia Pastor-Jane¹, Mar Cordellat-Martínez¹, Jose David Canovas-Garcia¹, Cristina Angulo-Martinez¹, Miquel Just-Sarobe¹
¹Dermatology, University Hospital Joan XXIII of Tarragona, Tarragona, Spain
Introduction
- 40** **Efficacy and improvement in quality of life in patients treated with brodalumab in real clinical practice: a case series of 31 patients**
Josep Pujol-Montcusi¹, Nerea Mohino-Farré¹, Clara Martin-Callizo¹, Laia Pastor-Jane¹, Mar Cordellat-Martínez¹, Jose David Canovas-Martinez¹, Cristina Angulo-Martinez¹, Miquel Just-Sarobe¹
¹Dermatology, University Hospital Joan XXIII of Tarragona, Tarragona, Spain
- 41** **Photodynamic therapy using nano-encapsulated peptides in the complex treatment of anogenital lichen sclerosis.**
Liaman Shamilova¹, Professor Elena Snarskaya¹
¹Sechenov First Moscow State Medical University, Moscow, Russia
- 42** **Cold aggravated IMQ-induced psoriatic skin via unbalanced lipid metabolism and fibroblast-adipocyte differentiation**
Feng Xue¹, Ce Shuai¹, Li Zhang¹, Hui Yang¹, Sheng Quan¹, Han Cao¹, Lihong Chen¹, Xia Li¹, Jie Zheng¹
¹Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University, School Of Medicine, Shanghai, China

- 43** **Machine Learning-Based Differential Diagnosis of Psoriasis and Atopic Dermatitis Using Clinical Data and Medical Images**
Rifaldy Fajar¹, Ratna Anjani Nirmawati¹, Riro Lambeta Huahua², Evita Mira Syailendra Pertiwi¹, Beti Leka Panjaro²
¹Computational Biology and Medicine Laboratory, Yogyakarta State University, Sleman, Indonesia
²Department of Dermatology and Venereology, Manokwari General Hospital, Manokwari, Indonesia
- 44** **Predicting Individuals with Psoriasis at Risk from Multiple Sclerosis**
Matthew T Patrick¹, Qinmengge Li², Nicole L Ward³, Johann E Gudjonsson¹, James T Elder¹, Lam C Tsoi¹
¹Department of Dermatology, University Of Michigan, Ann Arbor, United States
²Department of Biostatistics, University Of Michigan, Ann Arbor, United States
³Department of Dermatology, Vanderbilt University Medical Center, Nashville, United States
- 45** **Deciphering the autophagy-lysosomal pathway in relation to the immune-inflammatory ecosystem of psoriasis**
Magdalena Gabig-Cimińska¹, Marta Moskot¹, Martyna Kuczyńska¹, Katarzyna Zima¹
¹University of Gdańsk, Gdańsk, Poland
- 46** **Skin barrier function assessment: electrical impedance spectroscopy is less influenced by daily routine activities than transepidermal water loss**
Lisa Huygen¹, Pauline Marie Thys², Andreas Wollenberg³, Jan Gutermuth¹, Inge Kortekaas Krohn²
¹Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium
²Vrije Universiteit Brussel (VUB), SKIN Research Group, Brussels, Belgium
³Department of Dermatology and Allergy, Ludwig-Maximilian-University, Munich, Germany
- 47** **Bilastine in Refractory Chronic Spontaneous Urticaria: Disease Control and Cytokine Modulation in an Open-label Prospective Study**
Disha Chakraborty¹, Abhishek De¹, Kiran Godse²
¹Calcutta National Medical College And Hospital, Kolkata, India, Kolkata, India
²D. Y Patil University, India
- 48** **JAK1/2 pathway-specific treatment of generalized granuloma annulare with baricitinib**
Annelien Jadoul¹, Lisa Huygen¹, Gaëlle Leemans³, Martine Grosber¹, Inge Kortekaas Krohn², Jan Gutermuth¹
¹Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Dermatology, Brussels, Belgium
²Vrije Universiteit Brussel (VUB), SKIN Research Group, Brussels, Belgium
³Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Pathology, Brussels, Belgium



- 49** A pink nodule developed after COVID-19 vaccine
Conghui Li¹, Yanyan Feng¹
¹Chengdu Second People's Hospital, Chengdu, China
- 50** Transcriptomic Analysis of Plaque Psoriasis during Anti-IL-17A Biologic Therapy and Drug Withdrawal
Lihong Chen¹, Li Zhang¹, Xintian Xu², Qiannan Xu¹, Feng Xue¹, Pei Hao², Xia Li¹, Jie Zheng¹
¹Ruijin Hospital, Shanghai Jiao Tong University, School Of Medicine, Shanghai, China
²CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China
- 51** Rapid clinical improvement of refractory subacute cutaneous lupus erythematosus with oral TYK2 inhibitor deucravacitinib: a case report
Bernadett Kurz¹, Irina Ivanova¹, Konstantin Drexler¹, Mark Berneburg¹, Florian Günther², Dennis Niebel¹
¹University Hospital Regensburg, Regensburg, Germany
²Asklepios Klinikum, Bad Abbach, Germany
- 52** Bricilib - a new strategy for the treatment of psoriasis targeting eukaryotic translation initiation factor 4E
Nicole Golob-Schwarzl¹, Johannes Pilic¹, Azelma Vrebo¹, Chiara Reinprecht¹, Theresa Benezeder¹, Natalie Bordag¹, Clemens Painsi², Peter Wolf¹
¹Department of Dermatology, Medical University of Graz, Austria, Graz, Austria
²Department of Dermatology and Venereology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria, Klagenfurt, Austria
- 53** Intracranial Hypertension Following Alitretinoin Treatment for Chronic Hand Eczema: A Case Report
Byeol Han¹, Yun Jeong Choi², Jung Min Lee², Yu Jin Lee², Yeon Seok Lee², June Hyunkyung Lee²
¹Department of Dermatology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, South Korea
²Department of Neurology, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu-si, South Korea
- 54** A CHRONIC INFLAMMATORY ENVIRONMENT REVEALED IN AGE SPOTS FROM BOTH EUROPEAN AND ASIAN VOLUNTEERS
Constance Alvarez-Duchesne¹, Emilie Bourreau¹, Emilie Warrick¹, Karima Labiad-Hadji¹, Françoise Bernerd¹, Christine Duval¹
¹L'Oréal Research and Innovation, Aulnay-Sous-Bois, France

55 Dupilumab Treatment Normalizes Skin Barrier Function and Improves Patient-Reported Outcomes in Patients Aged 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis

Michael J. Cork^{1,2}, Donald Y.M. Leung³, Peck Ong⁴, Simon G. Danby¹, Marco Ramirez-Gama³, Shannon Garcia³, Patricia Taylor³, Joseph Zahn⁵, Amy Praestgaard⁶, Gabriel Bologna⁶, Annie Zhang⁶

¹Sheffield Dermatology Research, University of Sheffield, Sheffield, UK

²Sheffield Children's Hospital, Sheffield, UK

³National Jewish Health, Denver, USA

⁴Children's Hospital Los Angeles, University of Southern California, Los Angeles, USA

⁵Regeneron Pharmaceuticals Inc., Tarrytown, USA

⁶Sanofi, Cambridge, USA

56 Targeting the IL-15 signaling pathway prevents the formation of cutaneous TRM and limits flare-ups of allergic contact dermatitis

Roxane Cuzin¹, Vanina Lenief¹, Marine-Alexia Lefevre¹, Aurélie Guironnet-Paquet¹, Amandine Mosnier¹, Audrey Nosbaum^{1,2}, Axel Villani^{1,2}, Jean-Francois Nicolas^{1,2}, Marc Vocanson¹

¹CIRI-Centre International de Recherche en Infectiologie; Université de Lyon; Ecole Normale Supérieure de Lyon; Lyon, France

²Allergology and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Bénite, France

57 Mast cells as potential drivers of inflammation in psoriasis

Theresa Benezeder¹, Johannes Woltsche¹, Natalie Bordag¹, Andrea Teufelberger¹, Isabella Perchthaler¹, Wolfgang Weger¹, Alexandra Gruber-Wackernagl¹, Wolfgang Salmhofer¹, Clemens Painsi², Karin Pankratz³, Amin El-Heliebi³, Magda Babina^{4,5}, Rachael Clark⁶, Peter Wolf¹

¹Department of Dermatology and Venereology, Medical University Of Graz, Graz, Austria

²Department of Dermatology, State Hospital Klagenfurt, Klagenfurt, Austria

³Division of Cell Biology, Histology and Embryology, Medical University of Graz, Graz, Austria

⁴Institute of Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany

⁵Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany

⁶Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA

58 Low density neutrophils show higher propensity to infiltrate skin in experimental model of psoriasis compared with conventional neutrophils.

Joanna Skrzeczynska-Moncznik¹, Patrycja Kwiecinska¹, Alicja Dziadowiec¹, Joanna Cichy¹

¹Faculty of Biochemistry, Biophysics And Biotechnology, Jagiellonian Univ., Krakow, Poland



59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege

Karoline Strobl¹, Jörg Klufa¹, Regina Jin¹, Lena Artner-Gent¹, Dana Krauß¹, Philipp Novoszel¹, Johanna Strobl², Georg Stary², Igor Vujic³, Johannes Griss², Martin Holcman¹, Mathias Farlik², Bernhard Homey⁴, Maria Sibilia¹, Thomas Bauer¹

¹Center For Cancer Research, Comprehensive Cancer Center, Medical University Of Vienna, Vienna, Austria

²Department of Dermatology, Medical University of Vienna, Vienna, Austria

³Department of Dermatology and Venereology, Medical Institution Rudolfstiftung, Vienna, Austria

⁴Department of Dermatology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany

60 Racial Disparities In Cardiovascular Outcomes And Serum Lab Values In Hidradenitis Suppurativa: A Bivariate Analysis

Afua Ofori-Darko¹, Alison Treichel², Thomas McCormick², Kevin Cooper²

¹Case Western Reserve University School Of Medicine, Cleveland, United States

²University Hospitals Cleveland Medical Center, Cleveland, United States

61 Influence of dupilumab on HSV-specific immune response in atopic dermatitis

Stephan Traidl^{1,2}, Leonard Harries¹, Petra Kienlin¹, Gabriele Begemann¹, Lennart M. Roesner^{1,2}, Thomas Werfel^{1,2}

¹Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany

²Cluster of Excellence RESIST (EXC 2155), Hannover Medical School,

62 Single cell transcriptome revealed the role of CCL19+ inflammatory epithelial cells in pemphigus

Yiyi Wang¹, Shan Zhao², Xiwen Zhang¹, Xingli Zhou¹, Yue Xiao¹, Tongying Zhan¹, Xuyang Xia², Yang Shu^{2,3}, Heng Xu^{2,4}, Wei Li¹

¹Department of Dermatology & Rare Diseases Center, West China Hospital of Sichuan University, Chengdu, China

²State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, China

³Gastric Cancer Center, West China Hospital of Sichuan University, Chengdu, China

⁴Department of Laboratory Medicine, Research Center of Clinical Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China

63 Comparison of the disease survival of biologics for the treatment of moderate-to-severe psoriasis: real-world data

Seung-Min Oh¹, Kyong-Won Kang¹, Da-Hyun Kang², Soon-Hyo Kwon², Bark-Lynn Lew², Min Kyung Shin¹, Ki-Heon Jeong¹

¹Department of Dermatology, Kyunghee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea

²Department of Dermatology, Kyung Hee University Hosital at Gang-dong, Kyung Hee University College of Medicine, Seoul, South Korea

- 64** **Contribution of MAIT cells in the development of Hidradenitis Suppurativa**
 Alexis Dumas¹, Inès CHIRCOP^{1,2}, Amandine MOSNIER¹, Jean-François NICOLAS^{1,3},
 Denis JULLIEN^{1,2}, Marc VOCANSON¹, Axel VILLANI^{1,2}
¹Inserm U111 international infectious diseases research center (CIRI), Lyon, France
²Dermatology department, Hôpital Edouard Herriot, Lyon, France
³Allergology and Clinical Immunology department, CHLS, Lyon, France
- 65** **Persistent Cutaneous Lesions of Darier Disease are Associated with Second-Hit Somatic Variants in ATP2A2 Gene**
 Lihi Atzmony^{1,2}, Fadia Zagairy³, Michael Ziv³, Nada Danial Farran³, Roni Dudziok-Gad³,
 Eran Cohen Barak^{3,4}
¹Rabin Medical Center, Petach Tikva, Israel
²Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
³Department of Dermatology, Emek Medical Center, Afula, Israel
⁴Rappaport Faculty of Medicine, Technion, Haifa, Israel
- 66** **'Microneedle' A new horizon of intradermal therapeutics**
 Waleed Faisal¹, Ziad Sartawi¹, Ryan Bamsey¹
¹University College Cork, Cork, Ireland
- 67** **Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies**
 Brett King¹, Paradi Mirmirani², Kristen Lo Sicco³, Yuval Ramot⁴, Rodney Sinclair⁵, Leila Asfour⁶,
 Khaled Ezzedine⁷, Carle Paul⁸, Roger A. Edwards⁹, Urs Kerkmann¹⁰, Dalia Wajsbrot¹¹,
 Samuel H. Zwillich¹², Alexandre Lejeune¹³
¹Yale School of Medicine, New Haven, USA
²The Permanente Medical Group, Vallejo, USA
³The Ronald O Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, USA
⁴Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel
⁵Sinclair Dermatology, Melbourne, Australia
⁶The Dermatology Centre, Salford Royal Hospital, Salford, UK
⁷Department of Dermatology, Henri Mondor University Hospital and EpiDermE, Paris, France
⁸Department of Dermatology, Toulouse University and CHU, Toulouse, France
⁹Health Services Consulting Corporation, Boxborough, USA
¹⁰Pfizer Pharma GmbH, Berlin, Germany
¹¹Pfizer Inc, New York, USA
¹²Pfizer Inc, Groton, USA
¹³Pfizer Inc, Paris, France



68 **EV0756 is a novel MRGPRX2 antagonist that potently inhibits human mast cell degranulation in response to multiple agonists – potential treatment for CSU and beyond**

Jamie Harden¹, Jelle Folkerts², See-Ying Tam², Stefan Frischbutter^{3,4}, Magda Babina^{3,4},

Hans E Hofland¹, Jeegar P Patel¹, Marcus Maurer^{3,4}, Stephen J Galli²

¹*Evmmune, Palo Alto, United States*

²*Stanford University, Palo SItto, United States*

³*Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany*

⁴*Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany*

69 **Risk-Benefit Appraisal of Systemic JAK Inhibitors for Alopecia Areata: A Comprehensive Meta-Analysis Assessing Safety and Adverse Effects**

Luana Moury Fernandes Sanchez¹, Andreia Almeida Lopes², Arianne Beatriz Freitas

Rodrigues Santos³, Beatriz Costa de Carvalho Silva⁴, Carolina Portela Mendes⁵,

Isabella Bueno Pereira da Rocha⁶, Jade Zarichta Costa⁷, Juliana Secomandi Machado⁸,

Julliana Camargo de Barros⁹, Maria Eduarda Mendes Cruz¹⁰, Sofia Daher Pimentel¹¹

¹*Mount Sinai Hospital, New York, United States*

²*Christus University Center , Fortaleza, Brazil*

³*University of Medicine Uninassau Boa Viagem , Recife, Brazil*

⁴*Pernambuco Faculty of Health , Recife, PE*

⁵*Potiguar University , Natal, Bazil*

⁶*University of Cuiabá , Cuiaba, Bazil*

⁷*Federal University of Santa Catarina , Florianopolis, Brazil*

⁸*University of Mogi das Cruzes , Sao Paulo, Brazil*

⁹*São Camilo University Center , Sao Paulo, Brazil*

¹⁰*Juazeiro do Norte Medicine College , Natal, Brazil*

¹¹*Petrópolis Medicine University, Petropolis, Brazil*

70 **The long-term effectiveness of biologics in Chinese patients with psoriasis by body regions: A retrospective real-life study**

Yue Xiao¹, Yiyi Wang¹, Hongxiang Hu¹, Furong Li¹, Wenyao Mi¹, Jingya Gao¹, Jinqiu Wang¹,

Gaojie Li¹, Yuanxia Gu¹, Mengmeng Li¹, Dan Hao¹, Wei Yan¹, Wei Li¹

¹*Department of Dermatology and Venereology, West China Hospital, Chengdu, China*

71 **Video-based education as an adjunct treatment for pediatric atopic dermatitis: A randomized, assessor-blind, controlled trial**

Arbie Sofia Merilleno^{1,2}, Czarina Chavez², Mae Quizon¹

¹*Rizal Medical Center, Pasig City, Philippines*

²*Montreal Dermatology Research Institute/International Eczema Council, Canada*

- 72 Eubacterium rectale is a key marker of altered gut microbiota in psoriasis and psoriatic arthritis**
Yue Xiao¹, Yiyi Wang¹, Bangzhuo Tong², Yuanxia Gu¹, Xingli Zhou¹, Ning Zhu², Xiaomin Xu², Xiaochen Yin², Yan Kou², Yan Tan², Huaping Zheng¹, Cheng Deng¹, Jincheng Wang², Wei Li¹
¹*Department of Dermatology and Venereology, West China Hospital, Chengdu, China*
²*Xbiome, Shenzhen, China*
- 72 Which Systemic agent for which Vitiligo patient**
Ajith Cy¹
¹*McMaster University, Waterloo, Canada*
- 74 Interstitial fluid immunophenotyping characterizes topical chlormethine-induced changes in the tumor micro-environment in early-stage mycosis fungoides.**
Selinde Wind¹, Rianne Rijneveld¹, Hendrika Grievink², Catherine Mergen³, Tessa Niemeyer - van der Kolk¹, Koen Quint⁴, Maarten Vermeer⁴, Robert Rissmann³
¹*Centre for Human Drug Research, Dermatology, Leiden, Netherlands*
²*Centre For Human Drug Research, Immunology, Leiden, Netherlands*
³*Leiden Academic Center for Drug Research and Centre for Human Drug Research, Leiden, Netherlands*
⁴*Leiden University Medical Center, Leiden, Netherlands*
- 75 Downstream effects of IL-13R α 1 blockade on Th2-driven inflammation and Th1 immune axis activation in atopic dermatitis**
Sriya V. Reddy¹, Zachary Bordeaux¹, Ahmad Rajeh², Darshan Sivaloganathan², Hannah Cornman², Anusha Kambala², Jackson Adams¹, Carl Firth³, Ferda Cevikbas³, Shawn G. Kwatra², Madan M. Kwatra¹
¹*Department of Anesthesiology, Duke University Medical Center, Durham, USA*
²*Department of Dermatology, Johns Hopkins University, Baltimore, USA*
³*ASLAN Pharmaceuticals, San Mateo, USA and Singapore*
- 76 Neuromodulation beyond itch is blocked by targeting IL-13R α 1 with eblasakimab**
Yannick Miron¹, Paul Miller¹, Carl Firth², Ferda Cevikbas²
¹*AnaBios Corporation, San Diego, USA*
²*ASLAN Pharmaceuticals, San Mateo, USA and Singapore*



77 JNJ-77242113 treatment induces strong systemic pharmacodynamic response versus placebo in patients with plaque psoriasis: Results from the phase 2, FRONTIER 1 study

Andreas Pinter¹, Kilian Eyerich², Amy Paller³, Arun Kannan⁴, David Strawn⁴, Daniel Horowitz⁴, Sunita Bhagat⁴, Dylan Richards⁴, Darren Ruane⁵, Bradford McRae⁶, Ya-Wen Yang⁷, Megan Miller⁴, Cynthia DeKlotz⁴, Robert Bissonnette⁸

¹Goethe University Frankfurt, Frankfurt, Germany

²University of Freiburg, Freiburg im Breisgau, Baden-Württemberg, Germany

³Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

⁴Janssen Research & Development, LLC, Spring House, PA, USA

⁵Janssen Research & Development, LLC, La Jolla, CA, USA

⁶Janssen Research & Development, LLC, Cambridge, MA, USA

⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

⁸Innovaderm Research, Montreal, Quebec, Canada

Introduction: JNJ-77242113, a first-in-class oral IL-23R antagonist peptide, demonstrated significantly greater efficacy vs placebo (PBO) for moderate-to-severe plaque psoriasis in FRONTIER-1.

78 A Phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for moderate-to-severe plaque psoriasis: Efficacy of overall and scalp psoriasis responses from FRONTIER 1

Robert Bissonnette¹, Andreas Pinter², Laura Ferris³, Sascha Gerdes⁴, Phoebe Rich⁵, Ronald Vender⁶, Ya-Wen Yang⁷, Megan Miller⁸, Yaung-Kaung Shen⁸, Cynthia DeKlotz⁸, Kim A. Papp⁹

¹Innovaderm Research, Montreal, Quebec, Canada

²Goethe University Frankfurt, Frankfurt, Germany

³University of Pittsburgh, Pittsburgh, PA, USA

⁴Center for Inflammatory Skin Diseases, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany

⁵Oregon Dermatology and Research Center, Portland, OR, USA

⁶McMaster University, Hamilton, ON, Canada

⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

⁸Janssen Research & Development, LLC, Spring House, PA, USA

⁹Alliance Clinical Trials and Probitry Medical Research, Waterloo, ON, Canada and University of Toronto, Toronto, ON, Canada

- 79** **The Impact of Inflammation on the Absolute Concentration of Albumin and α 1-Acid Glycoprotein in Porcine Skin**
 Simon Schwingenschuh¹, Elisabeth Hofmann², Peter Reisenegger¹, Michael Joebstl¹, Peter M. H. Heegaard³, Jessica Schweiger¹, Eva-Maria Prugger¹, Maria Ratzner¹, Anita Eberl¹, Reingard Raml¹, Petra Kutzbeck², Carolin Tetyczka⁴, Eva Roblegg⁴, Thomas Birngruber¹
¹HEALTH – Institute for Biomedical Research and Technologies, Joanneum Research, Graz, Austria
²COREMED – Centre for Regenerative and Precision Medicine, Joanneum Research, Graz, Austria
³Innate Immunology and Metabolism Group, Department of Health Technology, Technical University of Denmark, Kgs. Lyngby, Denmark
⁴Institute of Pharmaceutical Sciences, Pharmaceutical Technology & Biopharmacy, University of Graz, Graz, Austria
- 80** **Morphea-like reaction from red tattoo in a patient with systemic sclerosis**
 Grace Hobayan¹, Jasmine Thai¹, Judith Lin¹
¹The Ohio State University, Columbus, United States
- 81** **Cutaneous neurogenic inflammation mediated by TRPV1-NGF-TRKA pathway activation in rosacea is exacerbated by the presence of Demodex mites**
 Sang Gyu Lee¹, Jihee Kim^{2,3}, Young In Lee^{1,3}, Jemin Kim^{2,3}, Seul Choi², Seoyoon Ham¹, Ju Hee Lee^{1,3}
¹Department Of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, South Korea
²Department of Dermatology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, South Korea
³Scar Laser and Plastic Surgery Center, Yonsei Cancer Hospital, Seoul, South Korea
- 82** **IL-9 sensitizes human pathogenic Th2 cells to pro-inflammatory IL-18 signals in atopic dermatitis**
Stefanie Schärli¹, Fabian Luther¹, Oliver Steck¹, Jacob P. Thyssen², Nicole L. Bertschi¹, Christoph Schlapbach¹
¹Department Of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland, Bern, Switzerland
²Department of Dermatology and Allergology, Gentofte Hospital, Hellerup, Denmark, Hellerup, Denmark
- 83** **Transcriptomic Meta-Analysis and Deconvolution Approaches Unveil Cellular Dynamics in Scarring and Non-Scarring Primary Lymphocytic Alopecias**
Jesus Gay-Mimbrera¹, Irene Rivera-Ruiz¹, Pedro Gómez-Arias², Miguel Juan-Cencerrado¹, Macarena Aguilar-Luque¹, Juan Ruano²
¹Inflammatory Immune-Mediated Chronic Skin Diseases Laboratory, Córdoba, Spain
²IMBIC and Department of Dermatology, Reina Sofía University Hospital, Córdoba, Spain



- 84** **Partial Restoration of Scalp Microbiota in Alopecia Areata with JAK Inhibitors**
Pedro Gómez-Arias², Irene Rivera-Ruiz¹, Miguel Juan-Cencerrado¹, Macarena Aguilar-Luque¹, Silvia Sánchez-González³, Adriana Ortega-Hernández³, Dulcenombre Gómez-Garre³, Jesus Gay-Mimbrera¹, Juan Ruano²
¹*Inflammatory Immune-Mediated Chronic Skin Diseases Laboratory, IMIBIC, Cordoba, Spain*
²*IMIBIC and Department of Dermatology, Reina Sofía University Hospital, Cordoba, Spain*
³*Laboratory of Vascular Biology and Microbiota, Hospital Clínico San Carlos-Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain*
- 85** **Microbiological diversity among palmoplantar dermatoses patients**
Vanda Bondare-Ansberga¹, Lelde Reinberga¹, Ilona Hartmane², Ingmārs Mikažāns²
¹*Rīga Stradiņš university, Riga, Latvia*
²*Rīgas 1st hospital, Riga, Latvia*
- 86** **To assess the meibomian gland involvement in patients of rosacea using ocular surface interferometer in skin of colour**
Pankaj Das¹, Piyush Chaturvedi²
¹*Armed Forces Medical College, Pune, India*
²*Base Hospital Delhi Cantt , New Delhi, India*
- 87** **Current state of long-term management in generalized pustular psoriasis (GPP) in Germany - results of a Delphi consensus study**
Isaak Effendy¹, Sascha Gerdes², Wiebke K Peitsch³, Tsianakas Athanasios⁴, Thomas M Zimmermann⁵, Tobias Vogelmann⁶
¹*Department of Dermatology, Venereology and Allergology, University Hospital East Westphalia/ OWL, University of Bielefeld, Campus Klinikum Bielefeld, Bielefeld, Germany*
²*Center Center for Inflammatory Skin Diseases, Department of Dermatology, Venereology and Allergology, University Hospital Schleswig- Holstein - Campus Kiel, Kiel, Germany*
³*Department of Dermatology and Phlebology, Vivantes Klinikum im Friedrichshain, Berlin, Germany*
⁴*Department of Dermatology and Allergology, Specialized Hospital Bad Bentheim, Bad Bentheim, Germany*
⁵*Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,*
⁶*LinkCare GmbH, Ludwigsburg, Germany*
- 88** **ANBO32, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells**
Kenneth Luu¹, Bruce Randazzo¹, Eric Hare¹, Matthew Hsu¹, Chris Haines¹, Martin Dahl¹, Cailin Sibley¹, Paul Lizzul¹
¹*AnaptysBio, San Diego, United States*

89 A Phase 2b, Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Moderate-to-Severe Atopic Dermatitis

Benjamin Ehst¹, Jonathan Silverberg², Paul Lizzul³, Kenneth Luu³, Jocelyne Papacharalambous³, Priya Raina³, Bruce Randazzo³, Cailin Sibley³, Emma Guttman-Yassky⁴

¹Oregon Medical Research Center, Portland, USA

²The George Washington University School of Medicine and Health Sciences, Washington DC, USA

³AnaptysBio, San Diego, USA

⁴Icahn School of Medicine at Mount Sinai, New York, USA

90 Exploring the therapeutic potential of DHODH inhibitor farudodstat for alopecia areata treatment in a novel ex vivo model of human hair follicle immune privilege collapse

Thomas Rouillé¹, Silvia Barbosa¹, Ana Steinhoff¹, Ilaria Piccini¹, Janin Edelkamp¹, Alexandre Kaoukhov², Carl Firth², Ferda Cevikbas², Marta Bertolini¹

¹Monasterium Laboratory, Münster, Germany

²ASLAN Pharmaceuticals, San Mateo, USA and Singapore

91 Vitiligo Biomarker CXCL10 Correlates With Clinical Response in the TRuE-V Mechanism of Action Study

Angelina Volkova¹, Deanna Kornacki¹, Susan Smith¹

¹Incyte Corporation, Wilmington, USA

92 Prevalence and incidence of psoriatic arthritis among patients with psoriasis and risk factors for psoriatic arthritis in Republic of Korea: A nationwide database study

Chul Hwan Bang¹, Yoon-Seob Kim², Eun Suk Jung³, JiYoon Ahn⁴, Jung-Ae Kim⁴, Chul Jong Park²

¹Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

²Department of Dermatology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

³Janssen Korea Ltd., Seoul, Republic of Korea

⁴IQVIA Korea Ltd., Seoul, Republic of Korea,



93 Guselkumab binding to CD64 and simultaneous capture of IL-23 mediates internalization of IL-23 by CD64+ macrophages

James G. Krueger¹, Kilian Eyerich^{2,3}, Robert Bissonnette⁴, Brain Stoveken⁵, Deepa Hammaker⁶, Kristin Leppard⁵, John Hartman⁵, Indra Sarabia⁶, Phuc Bao⁶, Eilyn Lacy⁶, Kacey Sachen⁶, Iain B. McInnes⁷, Steven Fakharzadeh⁸, Anne Fourie⁶

¹*The Rockefeller University, Laboratory for Investigative Dermatology, New York, NY, USA,*

²*University of Freiburg, Freiburg, Germany,*

³*Karolinska Institute, Department of Medicine - Division of Dermatology and Venereology, Stockholm, Sweden,*

⁴*Innovaderm Research Inc, Montreal, Quebec, Canada,*

⁵*Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, USA,*

⁶*Janssen Research & Development, LLC, Immunology, San Diego, CA, USA,*

⁷*University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, UK,*

⁸*Janssen Research & Development, LLC, Horsham, PA, USA,*

94 Maintenance of efficacy and safety with lebrikizumab up to one year of treatment in patients with moderate-to-severe atopic dermatitis with or without topical corticosteroids

Emma Guttman-Yassky¹, Stephan Weidinger², Jonathan Silverberg³, Melinda Gooderham⁴, Jacob Thyssen⁵, Alan Irvine⁶, Hany Elmaraghy⁷, Chitra Natalie⁷, Chaoran Hu⁷, Evangeline Pierce⁷, Esther Garcia Gil⁸, Eric Simpson⁹

¹*Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA*

²*Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany*

³*Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, USA*

⁴*Skin Centre for Dermatology, Peterborough, Canada*

⁵*Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark*

⁶*Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland*

⁷*Eli Lilly and Company, Indianapolis, USA*

⁸*Almirall, S.A., Barcelona, Spain*

⁹*Oregon Health & Science University, Portland, USA*

95 Mapping single-cell trajectories upon mTOR inhibition over time in patients with granulomatous disease

Kveta Brazdilova^{1,2}, Anna Redl^{1,2}, Luisa Unterluggauer¹, Lisa Kleissl^{1,2}, Thomas Krausgruber^{2,3}, Thomas Weichhart⁴, Christoph Bock^{2,3}, Georg Stary^{1,2}

¹*Medical University of Vienna, Department of Dermatology, Vienna, Austria*

²*CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria*

³*Medical University of Vienna, Institute of Artificial Intelligence, Center for Medical Data Science, Vienna, Austria*

⁴*Medical University of Vienna, Institute of Medical Genetics, Center for Pathobiochemistry and Genetics, Vienna, Austria*

96 Dermal open flow microperfusion (dOFM) to monitor local tissue response after dupilumab treatment in lesional and non-lesional skin of atopic dermatitis patients

Katrin Tiffner¹, Barbara Ehall², Anita Eberl¹, Manfred Bodenlenz¹, Thomas Pircher², Thomas Birngruber¹, Frank Sinner^{1,2}, Thomas Pieber^{1,2}

¹Health - Joanneum Research Forschungsgesellschaft mbH, Graz, Austria

²Division for Endocrinology and Diabetology, Department for Internal Medicine, Medical University of Graz, Graz, Austria

97 Skewed polyamine metabolism leads to functional defects in regulatory T cells during chronic inflammation

Teresa Neuwirth^{1,2}, Daniel Malz^{2,4}, Nara Marella², Lisa Kleissl¹, Anna Redl¹, Thomas Hannich², Davide Seruggia^{2,3}, Jörg Menche^{2,4}, Georg Stary^{1,2}

¹Medical University Of Vienna, Vienna, Austria

²CeMM Research Center for Molecular Medicine, Vienna, Austria

³St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria

⁴Max Perutz Labs, Department of Structural and Computational Biology, University of Vienna, Vienna, Austria

98 Long-lasting efficacy following guselkumab induction therapy in mild psoriasis patients, results from a randomized, placebo-controlled exploratory clinical trial

Jannik Rouse^{1,2}, Menthe Bergmans^{1,3}, Laura van der Meulen^{1,5}, Lisa Pagan^{1,3}, Digna de Bruin^{1,3}, Marieke de Kam¹, Naomi Klarenbeek¹, Joke Bouwstra², Marieke Seyger⁴, Juul van den Reek⁴, Tessa Niemeyer-van de Kolk¹, Robert Rissmann^{1,2,3}, Martijn van Doorn⁵

¹Centre For Human Drug Research, Leiden, Netherlands

²Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands

³Leiden University Medical Centre, Leiden, Netherlands

⁴Department of Dermatology, Radboud University Medical Center, Nijmegen, Netherlands

⁵Department of Dermatology, Erasmus Medical Center, Rotterdam, Netherlands

99 Dupilumab Treatment Normalizes Intraepidermal Nerve Fiber Density in Patients with Moderate-to-Severe Atopic Dermatitis and Improves Patient-Reported Outcomes

Sonja Ständer¹, Konstantin Agelopoulos¹, Leigh Nattkemper², Jerry Bagel³, Amy Praestgaard⁴, Gabriel Bologna⁵, Madison Mack⁴, Joseph Zahn⁶, Annie Zhang⁴, Gil Yosipovitch²

¹Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany

²Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery and Miami Itch Center, University of Miami, Miami, USA

³Eczema Treatment Center of New Jersey, East Windsor, USA

⁴Sanofi, Cambridge, USA,

⁵Ivridata Life Science (contracted for Sanofi), Paris, France,

⁶Regeneron Pharmaceuticals Inc., Tarrytown, USA



100 Rapid and sustained improvement in sleep quality, anxiety, and depression in adults with moderate-to-severe atopic dermatitis with dupilumab treatment

Albert Chiou¹, Emmanuel During¹, Peter Foley², [Julia Fuchs](#)³, Marius Ardeleanu⁴, Jiangming Wu⁵, Zafer Ozturk⁶

¹Stanford University, Palo Alto, USA

²Skin Health Institute, Carlton, Australia

³Sanofi, Vienna, Austria

⁴Regeneron Pharmaceuticals Inc., Tarrytown, USA

⁵Sanofi, Bridgewater, USA,

⁶Sanofi, Cambridge, USA

101 Atopic dermatitis and psoriasis overlap: A new disease entity defined by spatial molecular analysis of atopic dermatitis and psoriasis

[Yun Jung Huh](#)¹, Seon-Pil Jin², Hyo Jeong Nam³, Seung Sam Paik⁴, Chung-Gyu Park⁵, James G. Krueger⁶, Jaehwan Kim⁷, Hyun Je Kim⁵, Jeong Eun Kim¹

¹Department of Dermatology, Hanyang University College of Medicine, Seoul, South Korea

²Department of Dermatology, Seoul National University College of Medicine, Seoul, South Korea

³Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, South Korea

⁴Department of Pathology, Hanyang University College of Medicine, Seoul, South Korea

⁵Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, South Korea

⁶Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA

⁷Department of Dermatology, University of California Davis, Sacramento, USA

102 Dermal delivery of AP39, a hydrogen sulphide donor, reduces inflammation associated with impaired wound healing in hyperglycaemic environments and increases wound closure rates

Mandeep Marwah¹, Lissette Sanchez-Aranguren¹, Karan Rana¹, Srikanth Bellary¹, Irundika Dias¹, Farah Raja¹, Hala Shokr²

¹Aston University, Birmingham, United Kingdom

²The University of Manchester, Manchester, United Kingdom

103 Elucidating the molecular link between psoriasis and skin cancer

[Panagiota Tsokkou](#)¹, Martin Holcman², Kamil Mieczkowski¹, Latifa Bakiri³, Maria Sibilia², Erwin F. Wagner^{1,3}

¹Laboratory Genes and Disease, Department of Dermatology, Medical University of Vienna (MUV), Vienna, Austria

²Center for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna (MUV), Vienna, Austria

³Laboratory Genes and Disease, Department of Laboratory Medicine, Medical University of Vienna (MUV), Vienna, Austria

104 Borrelia burgdorferi spirochetes cause vascular damage and neurogenic inflammation in Erythema migrans

Sophie Weninger¹, Sophie Müller¹, Mateusz Markowicz^{2,3}, Anna-Margarita Schötta³, Luisa Unterluggauer¹, Lisa Kleissl^{1,4}, Anna Redl^{1,4}, Hannes Stockinger³, Johanna Strobl^{1,4}, Georg Stary^{1,4}

¹Department of Dermatology, Medical University of Vienna, Vienna, Austria

²Austrian Agency for Food and Health Safety (AGES), Vienna, Austria

³Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria

⁴CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

105 AhR agonism by tapinarof regulates TH2 and TH17 cell function in human skin

Fabian Luther¹, Nicole Leonie Bertschi¹, Oliver Steck¹, Stefanie Schärli¹, Lea Taylor², Susanne Radonjic-Hoesli¹, Nikhil Yawalkar¹, Dagmar Simon¹, Christoph Schlapbach¹

¹Department of Dermatology, Inselspital Bern, Bern, Switzerland

²Interfaculty Bioinformatics Unit and Swiss Institute of Bioinformatics, Bern, Switzerland

106 Dupilumab treatment in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial

Eric Simpson¹, Jonathan Silverberg², Margitta Worm³, Golar Honari⁴, Koji Masuda⁵, Ewa Sygula⁶, Jennifer Maloney⁷, Leda Mannent⁹, Jing Xiao⁷, Ariane Dubost-Brama⁹, Ashish Bansal⁷

¹Oregon Health & Science University, Portland, USA

²The George Washington School of Medicine and Health Sciences, Washington, USA

³Charité-Universitätsmedizin Berlin, Berlin, Germany

⁴Stanford University School of Medicine, Redwood City, USA

⁵Kyoto Prefectural University of Medicine, Kyoto, Japan

⁶Andrzej Mielecki Memorial Independent Public Clinical Hospital, Katowice, Poland

⁷Regeneron Pharmaceuticals, Inc., Tarrytown, USA

⁸Sanofi, Chilly-Mazarin, France

107 Tissue-restricted PD-1 agonists as local immune suppressants - a novel approach to treat cutaneous inflammation and autoimmune diseases

Kate Adams¹, Adam Curnock¹, Giovanna Bossi¹, David Overton¹, Randeep Singh¹, Bakhtbilland Khan¹, Ohannes Mazigi¹, Veronica Gonzalez¹, Eduardo Mateos-Diaz¹, Emma Charles¹, Kirsty Lang¹, Fiona McCann¹, Nicola Smith¹, Nitha Mulakkal¹, Libby Exley¹, Susan Aungier¹, Jae-Eun Lee¹, Sam Crine¹, Gloria Mesa-Gil¹, Richard Suckling¹, Vijaykumar Karupiah¹, Tamara Aleksic¹, Tara Mahon¹, JoAnn Suzich¹

¹Immunocore Ltd, Abingdon, United Kingdom



108 The role of Interleukin-1 driven inflammation in recessive dystrophic epidermolysis bullosa

Rebecca Kann¹, Morgan Anderson-Crannage^{1,2}, Alex M. Ascención³, Olga Ibanez-Solé³, Hongwen Zhu⁴, Edo Schaefer², Darcy Ottomanelli², Bruno Hochberg², Jian Pan², Wen Luo², Meijuan Tian², Yaya Chu², Mitchell S. Cairo^{1,2,5,6}, Ander Izeta^{3,7}, Yanling Liao²

¹New York Medical College, Valhalla, United States

²Department of Pediatrics, New York Medical College, Valhalla, USA

³Biodonostia Health Research Institute, Tissue Engineering Group, San Sebastian, Spain

⁴Guizhou Atlasus Technology Co., Ltd., China,

⁵Departments of Medicine, New York Medical College, Valhalla, USA

⁶Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, USA

⁷Department of Biomedical Engineering and Science, School of Engineering, Tecnun University of Navarra, Spain

109 UV-induced expression of human beta-defensin 124 (DEFB124), a novel antimicrobial peptide with anti-S. aureus potential: is it a mediator of phototherapy in AD?

Aaroh Anand Joshi¹, Marc Vocanson², Jean-Francois Nicolas^{2,4}, Peter Wolf^{1,3}, Vijaykumar Patra^{1,2}

¹Department of Dermatology, Medical University Of Graz, Graz, Austria

²International Center for Infectiology Research, French Institute of Health and Medical Research, Lyon, France

³BioTechMed Graz, Graz, Austria

⁴Department of Allergology & Clinical Immunology, Lyon-Sud University Hospital, Lyon, France

110 Natural history of keloids: A sociodemographic analysis using structured and unstructured data

Yuji Yamaguchi¹, Elena Peeva², Anna Swenson³, Jessica K Paulus³, Yoojin Jung³, Stefan Weiss³, Brian Berman⁴, Prethibha George⁵, Oladayo Jagun⁵

¹Pfizer, Inc, Collegeville, United States

²Pfizer Inc, Cambridge, United States

³OMI Inc, Boston, United States

⁴University of Miami Miller School of Medicine, Miami, United States

⁵Pfizer Inc, New York, United States

111 Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be): data, scores and phenotypes since 2015

Stephanie Heudens¹, Anne-Sophie Sarkis¹, Mathieu Daoud¹, Mathilde Daxhelet¹, Farida Benhadou¹, Mariano Suppa¹, Laura Nobile¹, Jalila Karama¹, Hassane Njimi¹, Jonhatan M White¹, Veronique del Marmol¹

¹Université Libre De Bruxelles, Bruxelles, Belgium

- 112** PHOTSENSITIVE PSORIASIS SUCCESSFULLY TREATED WITH IXEKIZUMAB: A CASE REPORT
Raluca Ioana Ailincăi¹, Oana Mirela Tiuca¹, Liuba Garaga¹, Ovidiu S. Cotoi¹, Silviu Horia Morariu¹
¹Mures Clinical County Hospital, Targu Mures, Romania
- 113** Investigating the Role of ZAG Peptide in Attenuating Cellular Senescence: A clinical and in vitro study
Joohee Lee¹, Young In Lee^{1,2}, Sang Gyu Lee¹, Seoyoon Ham¹, Ju Hee Lee^{1,2}
¹Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
²Scar Laser and Plastic Surgery Center, Yonsei Cancer Hospital, Yonsei University College of Medicine, Seoul, Korea
- 114** Identifying the mechanism of tension-associated tissue fibrosis based on integrative single cell RNA sequencing analysis on keloid scar
Seoyoon Ham¹, Joohee Lee¹, Sang Gyu Lee¹, Jemin Kim¹, Jihee Kim¹, Won jai Lee¹, Ju Hee Lee¹, Young In Lee¹
¹Yonsei University College of Medicine, Seoul, South Korea
- 115** Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: Austrian subanalysis of 28-week interim data from the phase IV POSITIVE study
Wolfgang Weger¹, Barbara Gruber², Gudrun Ratzinger³, Leo Richter⁴, Paul-Gunther Sator⁵
¹Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria,
²Department of Dermatology, Klinikum Wels-Grieskirchen, Wels, Austria
³Department of Dermatology, Medical University of Innsbruck, Innsbruck, Austria
⁴Hautarztpraxis Leo Richter, Vienna, Austria
⁵Department of Dermatology, Klinik Hietzing, Vienna, Austria
- 116** Patient-reported well-being using tildrakizumab in a real-world setting: 28-week interim data in patients with nail psoriasis from the phase IV POSITIVE study
Wolfgang Weger¹, Barbara Gruber², Gudrun Ratzinger³, Paul-Gunther Sator⁴
¹Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria,
²Department of Dermatology, Klinikum Wels-Grieskirchen, Wels, Austria
³Department of Dermatology, Medical University of Innsbruck, Innsbruck, Austria
⁴Department of Dermatology, Klinik Hietzing, Vienna, Austria



- 117** **Molecular signatures of skin barrier defect and inflammation in Netherton syndrome uncovered by comparing patients to viable Spink5 knock-out mice**
Evgeniya Petrova¹, Jesus Maria Lopez-Gay Orts², Matthias Fahrner³, Florent Leturcq¹, Jean-Pierre de Villartay⁴, Claire Barbieux¹, Lam Tsoi⁵, Johann Gudjonsson⁵, Oliver Schilling³, Alain Hovnanian¹
¹INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute and University of Paris, Paris, France
²Institut Curie, PSL Research University, CNRS UMR 3215, INSERM U934, Paris, France
³Institute for Surgical Pathology, Medical Center, Faculty of Medicine, University of Freiburg, Germany; German Cancer Consortium (DKTK) and Cancer Research Center (DKFZ), Freiburg, Germany
⁴Imagine Institute, Laboratory "Genome Dynamics in the Immune System", INSERM UMR 11635, Paris, France
⁵Department of Dermatology, University of Michigan Medical School, Ann Arbor, USA
- 118** **Ca²⁺ metabolism permutations in Ps-inflammation activation**
Marta Moskot¹, Martyna Kuczyńska¹, Magdalena Gabig-Cimińska¹, Monika Ryba-Stanisławowska², Bartosz Słomiński²
¹University of Gdańsk, Gdańsk, Poland
²Medical University of Gdańsk, Gdańsk, Poland
- 119** **Mitochondrial Cristae-Level Morphological Alterations in Keratinocytes and Fibroblasts Induced by Psoriasis-like Inflammation**
Gabrielė Kulkovienė¹, Martyna Uldukytė¹, Jonas Šoliūnas¹, Viktorija Šalčiūtė², Milda Kairytė³, Ramunė Morkūnienė¹, Aistė Jekabsone^{2,3}
¹Department of Drug Chemistry, Lithuanian University Of Health Sciences, Kaunas, Lithuania
²Laboratory of Pharmaceutical Sciences Institute of Pharmaceutical Technologies, Lithuanian University Of Health Sciences, Kaunas, Lithuania
³Preclinical Research Laboratory for Medicinal Products Institute of Cardiology, Lithuanian University Of Health Sciences, Kaunas, Lithuania
- 120** **Interstitial fluid metabolomics shows dupilumab effects in the treatment of atopic dermatitis**
Fernanda Monedeiro¹, Barbara Ehall², Eva-Maria Prugger¹, Elmar Zügner¹, Eva Svehlikova², Thomas Pleber³, Katrin Tiffner¹, Christoph Magnes¹, Frank Sinner¹, Thomas Birngruber¹
¹HEALTH – Institute for Biomedical Research and Technologies, Joanneum Research, Graz, Austria
²Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
³HEALTH – Institute for Biomedical Research and Technologies, Joanneum Research & Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

- 121 A B cell-rich tumor microenvironment delineates cutaneous T cell lymphoma from benign inflammatory skin diseases**
Johanna Strobl^{1,4}, Ruoyan Li¹, Elizabeth F.M. Poyner², Louis Gardner³, Bayanne Olabi², Emily Stephenson², Rachel Botting², Laure Gambardella², Nina Zila⁴, Constanze Jonak⁴, Patrick Brunner⁸, Rowen Coulthard⁵, Chris M. Bacon⁵, Julia Nenonen⁹, Hanna Brauner⁹, Yang Wang⁷, Fan Bai⁶, Sarah A Teichmann¹, Muzlifah Haniffa^{1,2,3}
¹Wellcome Sanger Institute, Hinxton, Cambridge, United Kingdom
²Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
³Department of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne, United Kingdom
⁴Medical University of Vienna, Department of Dermatology, Vienna, Austria
⁵NovoPath, Department of Pathology, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
⁶Biomedical Pioneering Innovation Center (BIOPIIC), and School of Life Sciences, Peking University, Beijing, China
⁷Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China
⁸Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, United States
⁹Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden
- 122 Psoriasis modeling with an advanced immunocompetent in vitro system**
Marisa Meloni¹, Francesca Rescigno¹, Marion Le Roux¹, Caroline Baudoin¹, Christian Pellevoisin¹
¹Vitroscreen, Milan, Italy
- 123 Smart Imaging and Deep Learning for Objective Psoriasis Lesion Scoring: A Scarletred AI Proof-of-Concept Study**
Monika Molnarova¹, Rahul Ranjan¹, Jannik Rousel^{2,3}, Menthe Bergmans², Tessa Niemeyer-van der Kolk², Martijn van Doorn^{2,5}, Vasileios Exadaktylos², Robert Rissmann^{2,3,4}, Harald Schnidar¹
¹SCARLETRED Holding GmbH, Vienna, Austria
²Centre for Human Drug Research, Leiden, The Netherlands
³Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
⁴Leiden University Medical Centre, Leiden, The Netherlands
⁵Erasmus Medical Center, Rotterdam, The Netherlands
- 124 Lysyl Oxidase Regulates Extracellular Matrix Modifications in Psoriasis**
Parvaneh Balsini¹, David Samardzic¹, Pauline Weinzettl¹, Maria Buchberger¹, Nina Zila¹, Dörte Symmank¹, Wolfgang Weninger¹, Karin Pfisterer¹
¹Department of Dermatology, Medical University of Vienna, Vienna, Austria



- 125** **Electrical impedance spectroscopy evaluates organotypic epidermis formation and skin barrier function in vitro**
Noa van den Brink¹, Felicitas Pardow¹, Luca Meesters¹, Hanna Niehues¹, Ivonne van Vlijmen-Willems¹, Diana Rodijk-Olthuis¹, Susan Roelofs², Matthew Brewer³, Ellen van den Bogaard¹, [Jos Smits](#)^{1,4}
¹*Radboud University Medical Center (Radboudumc), Nijmegen, Netherlands*
²*Locsense B.V., Enschede, Netherlands*
³*University of Rochester Medical Center, Rochester, United States of America,*
⁴*Heinrich Heine University, Düsseldorf, Germany*
- 126** **The aryl hydrocarbon receptor regulates epidermal differentiation through transient activation of TFAP2A**
[Jos Smits](#)^{1,2}, Jieqiong Qu^{1,3}, Felicitas Pardow^{1,3}, Noa van den Brink¹, Diana Rodijk-Olthuis¹, Ivonne van Vlijmen-Willems¹, Simon van Heeringen³, Patrick Zeeuwen¹, Joost Schalkwijk¹, Huiqing Zhou^{1,3}, Ellen van den Bogaard¹
¹*Radboud University Medical Center (Radboudumc), Nijmegen, Netherlands*
²*Heinrich Heine University, Düsseldorf, Germany*
³*Radboud University, Nijmegen, The Netherlands*
- 127** **Drug Survival Analysis of Dupilumab and Associated Predictors in Patients with Atopic Dermatitis in South Korea: 4 Year, Single-center, Retrospective Study**
[Jung Jin Shin](#)¹, Tae Woong Seul¹, Hyun Woo Park¹, Hyo Yoon Kim¹, Sang Wook Son¹
¹*Korea University Ansan Hospital, Gyeonggi-do, South Korea*
- 128** **Individual and Niche Specific Multi-omics Signatures Shape the Functional Difference of Cutibacterium acnes in Normal and Diseased Skin**
[Tianze Yu](#)¹, Xiaoqiang Xu¹, Yang Liu², Shi Wu⁴, Zhuoqiong Qiu¹, Xiaochun Liu³, Chaoying Gu¹, Qiuyang Luo¹, Xiaokai Wang², Xu Yao³, Wei Li¹
¹*Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China*
²*01 Life Science technology, Shenzhen, China,*
³*Department of Allergy and Rheumatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China*
⁴*Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China*
- 129** **Targeted inhibition of EGFR reduces anti-microbial defense mechanisms at the hair canal**
[Lena Artner-Gent](#)¹, Regina Jin¹, Karoline Strobl¹, Dana Krauß¹, David Berry², Bela Hausmann², Tatiana Chontorotzea¹, Jörg Klufsa¹, Thomas Bauer¹, Maria Sibilia¹
¹*Center for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria*
²*Department of Microbiology and Ecosystem Science, University of Vienna, Vienna, Austria*

- 130** **Hidradenitis Suppurativa (HS) and Substance Use: Investigating Associations Between HS and Alcohol/Tobacco**
Victoria Jiménez¹, Mohammad Saleem², Rahima Begum³, Fazlur Rahman³, Nabihah Yusuf²
¹University Of Alabama At Birmingham Heersink School Of Medicine, Birmingham, United States
²University of Alabama at Birmingham Department of Dermatology , Birmingham, United States
³University of Alabama at Birmingham School of Public Health, Department of Biostatistics , Birmingham, United States
- 131** **The TRPM5 antagonist TPPO increases sebaceous lipogenesis and exerts pro-inflammatory effects via activation of Akt and p38 MAPK cascades**
Dorottya Ádám¹, József Arany¹, Orsolya Pető¹, Balázs I Tóth¹, Christos C Zouboulis², Habil. Attila Oláh¹
¹Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
²Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany
- 132** **Exploring the role of interleukin 15 in atopic dermatitis: Lesson from a humanized mouse model**
 Ilaria Piccini¹, Onur Egriboz¹, Aviad Keren², Anasua Pal¹, Karin Pappelbaum¹, Amos Gilhar², Alain Vicari³, Marta Bertolini¹
¹Monasterium Laboratory, Münster, Germany
²Skin Research Laboratory, Technion Institute, Haifa, Israel
³Calypto Biotech BV, Amsterdam, The Netherlands
- 133** **Short-term IL-23 neutralization reduces IL-23 transcription and number of activated pro-inflammatory mononuclear phagocyte (MNP) in psoriasis skin ex vivo**
 Lisa Zondler¹, Karin I Pappelbaum¹, Julianty Angsana², Joelle Obeid³, Kilian Eyerich⁴, Knut Schäkel⁵, Athanasios Tsianakas⁶, Sandra Malynn⁸, Monica WL Leung², Sven Wegner⁷, Marta Bertolini¹
¹Monasterium Laboratory, Münster, Germany
²Janssen R&D LLC, San Diego, USA
³Janssen, France
⁴University of Freiburg, Germany
⁵University Hospital Heidelberg, Germany
⁶Fachklinik Bad Bentheim, , Germany
⁷Janssen-Cilag, Germany
⁸Janssen Sciences, Ireland



134 Clinical response to IL-22RA1 blockade is associated with reduction of systemic inflammation

Diamant Thaçi¹, Melinda Gooderham², Vivian Laquer³, Charles Lynde⁴, Adam Reich⁵, Weily Soong⁶, Thomas Litman⁷, Daniel Madsen⁷, Britta Martel⁷, Ole Erik Soerensen⁷, Margitta Worm⁸

¹*Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany*

²*SKiN Centre for Dermatology, Queen's University and Probitry Medical Research, Peterborough, Canada*

³*First OC Dermatology Research, Fountain Valley, United States*

⁴*The Lynde Institute for Dermatology and Lynderm Research, Markham, Ontario, Canada, and Department of Medicine, University of Toronto, Toronto, Canada*

⁵*Department of Dermatology, University of Rzeszow, Rzeszow, Poland*

⁶*AllerVie Health-Alabama Allergy and Asthma Center, Birmingham, United States*

⁷*LEO Pharma A/S, Ballerup, Denmark,*

⁸*Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany*

135 p62, a pro-inflammatory protein in Atopic Dermatitis has a protective role in a mouse model of Psoriasis

Kamil Mieczkowski¹, Latifa Bakiri², Erwin F. Wagner^{1,2}

¹*Laboratory Genes and Disease, Department of Dermatology, Medical University of Vienna, Vienna, Austria*

²*Laboratory Genes and Disease, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria*

136 Adenosine receptors are novel regulators of human sebocyte biology

József Arany¹, Dorottya Ádám¹, Mariann Cseszlai¹, Tamara Nyitrai¹, Christos C. Zouboulis², Habil. Attila Oláh¹

¹*Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary,*

²*Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany*

137 Loss of myeloid Mcpip1 suppresses hair growth and development of epidermal papilloma of the skin

Weronika Szukała^{1,2}, Krzysztof Goryca³, Izabela Rumieńczyk³, Michał Mikula³, Leopold Eckhart⁴, Joanna Kozieł⁵, Jolanta Jura¹, Agata Lichawska-Cieślak¹

¹*Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology, Department of General Biochemistry, Krakow, Poland*

²*Jagiellonian University, Doctoral School of Exact and Natural Sciences, Krakow, Poland*

³*Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland*

⁴*Medical University of Vienna, Department of Dermatology, Vienna, Austria*

⁵*Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology, Department of Microbiology, Krakow, Poland*

- 138 Streptococcus agalactiae infection in a patient with psoriasis under treatment with an IL-17 antagonist**
Olga Pikou¹, Eufrosini Krikoni², Katerina Bakirtzi³, Ilias Papadimitriou³, Professor Elena Sotiriou³
¹Department of Dermatology and Venereology, General Hospital of Corfu, Corfu, Greece,
²Department of Laboratory Medicine and Microbiology, General Hospital of Corfu, Corfu, Greece
³1st Department of Dermatology and Venereology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
- 139 Cell-specific immune-modulatory functions of S100A8/A9 in Atopic Dermatitis**
Marta Palomo Irigoyen¹, Tim Hendrikx², Latifa Bakiri³, Silvia Hayer⁴, Johanna Schaffenrath³, Philipp Stark¹, Sylvia Knapp⁵, Erwin F. Wagner^{1,3}
¹Laboratory Genes and Disease, Department of Dermatology, Medical University of Vienna, Vienna, Austria
²Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
³Laboratory Genes and Disease, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria,
⁵Laboratory of Infection Biology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
- 140 Chronic hand eczema shares a common molecular signature regardless of atopic dermatitis status**
Jonathan Bar¹, Ester Del Duca¹, Eden David¹, Patrick Brunner¹, Robert Bissonnette², Emma Guttman-Yassky¹
¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, United States,
²Innovaderm Research, Montreal, Canada
- 141 Novel Emergence of Cutaneous Lupus Erythematosus as Adverse Effect of Acalabrutinib Therapy for Chronic Lymphocytic Leukemia**
Judith Lin¹, Madeline Fuller¹, Kerry Rogers¹, Abraham Korman¹
¹Ohio State University, Columbus, United States
- 142 Bidirectional TGF-beta signaling between CD8+ T cells and melanocytes determines melanocyte death in vitiligo, rescued by small-molecule receptor blocker**
Shany Sherman^{1,2}, Shuo Shan¹, Nuria Martinez Gutierrez², Erica Katz¹, Ken Okamura¹, Yuqing Wang¹, Kashayer Afshari², Nazgol Haddadi¹, Manuel Garber¹, JE Harris¹
¹Umass Chan Med School, Worcester, United States
²Rabin Medical Center, Petah Tikva, Israel



- 143** **Syndromic hidradenitis suppurativa in the European Registry for Hidradenitis Suppurativa (ERHS-Be)**
Anne-Sophie Sarkis¹, Stéphanie Heudens¹, Mathieu Daoud¹, Mathilde Daxhelet¹, Farida Benhadou¹, Mariano Suppa¹, Laura Nobile¹, Jalila Karama¹, Hassan Njimi¹, Jonathan M White¹, Véronique del Marmol¹
¹Dermatology Department, HUB – Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
- 144** **Dupilumab restores the equilibrium of keratins and desmosomal components, integral components of the skin barrier cornified envelope**
Elena Goleva¹, Evgeny Berdyshev¹, Simion Kreimer², Irina Bronova¹, Taras Lyubchenko¹, Shantanu Bafna³, Innocent Agueusop⁴, Robert Bissonnette⁵, Joseph Zahn⁶, Annie Zhang⁷, Donald Leung¹
¹National Jewish Health, Denver, USA
²Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, USA
³Sanofi, Bridgewater, USA,
⁴Sanofi, Frankfurt, Germany
⁵Innovaderm Research, Montreal, Canada
⁶Regeneron Pharmaceuticals Inc., Tarrytown, USA
⁷Sanofi, Cambridge, USA
- 145** **GREIN and ReactomeGSA - Simplifying the reuse of public data in multi-omics pathway analyses**
Alexander Grentner¹, Eliot Ragueneau¹, Chuqiao Gong¹, Henning Hermjakob¹, Johannes Griss¹
¹Department of Dermatology, Medical University of Vienna, Vienna, Austria
- 146** **Treatment with the oral CCR4 antagonist RPT193 results in meaningful changes in cutaneous biomarkers detected by transcriptomic profiling of tape strips**
Madeline Kim¹, Paola Facheris², Pedro Gomez-Arias³, Joel Correa Da Rosa¹, Ester Del Duca¹, Eugene Lurie⁴, Damian Trujillo⁴, Paul Kassner⁴, Laurence Cheng⁴, Dirk Brockstedt⁴, Amira Chowhury¹, Swaroop Bose¹, Yeriel Estrada¹, Robert Bissonnette⁵, Emma Guttman-Yassky¹
¹Icahn School of Medicine at Mount Sinai, Department of Dermatology, New York, United States,
²Department of Dermatology, IRCCS Humanitas Research Hospital, Rozzano, Italy
³Reina Sofia University Hospital, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain
⁴RAPT Therapeutics, South San Francisco, United States
⁵Innovaderm Research, Montreal, Canada

147 Serum Biomarkers in Pediatric Alopecia Areata with and without concurrent Atopic Dermatitis

Cathryn Sibbald¹, KA Buhler³, MY Choi³, David Croitoru², Elena Pope¹, MJ Fritzler³

¹*Division of Dermatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada*

²*University of Toronto, Toronto, Canada,*

³*Cumming School of Medicine, University of Calgary, Calgary, Canada*

148 Tape strips detect molecular alterations and cutaneous biomarkers in hidradenitis suppurativa skin

Kristina Navrazhina^{1,2}, Yael Renert-Yuval³, Saakshi Khattri¹, Hassan Hamade¹, Marguerite Meariman¹, Elizabeth Andrews¹, Madeline Kim¹, Monali NandyMazumdar¹, Diggpal S Gour¹, Swaroop Bose¹, Samuel C Williams², Sandra Garcet², Joel Correa da Rosa¹, Alice B. Gottlieb¹, James G. Krueger², Emma Guttman-Yassky¹

¹*Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY, United States,*

²*Laboratory for Investigative Dermatology, Rockefeller University, NY, United States,*

³*Tel Aviv University, Tel Aviv, Israel*

149 Underlying mechanisms of aberrant ultraviolet B (UVB)-induced skin inflammation in a STING gain-of-function mouse model

Jane Chuprin¹, Kevin Gao¹, Kristy Chiang¹, Khashayar Afshari¹, Nazgol Haddadi¹, Yuqing Wang Wang¹, Katherine Fitzgerald¹, Ann Rothstein¹, Mehdi Rashighi¹

¹*University Of Massachusetts Chan Medical School, Worcester, United States*

150 Skin CD69+CD62L+ TRM, a subset with renewal capacity gives rise to CD103+CD49a+ TRM

Elena Hoffer^{1,2}, Wenning Zheng^{1,2}, Zitti Beatrice³, Daniel Sortebeck^{1,2}, Rasmus Agerholm-Nielsen¹, Chenming Zhang¹, Trine Schönfeldt¹, Tilen Trselic¹, Sofia Papavasileiou⁴, Jaanika Kärner², Marcus Ehrström⁵, Jessica Gahm⁶, Jenny Mjösberg⁷, Josefina Lysell⁸, Niels Ødum¹, Yenan Bryceson³, Patrick Brunner⁹, Carmen Gerlach², Liv Eidsmo^{1,2}

¹*Leo Foundation Skin Immunology Center, Department of Immunology and Microbiology, University Of Copenhagen, København N, Denmark*

²*Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Unit of Rheumatology, Karolinska University Hospital, Solna, Sweden*

³*Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Huddinge, Sweden*

⁴*Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet and Unit of Immunology and Allergy, Karolinska University Hospital, Solna, Sweden*

⁵*Nordiska Kliniken, Stockholm, Sweden*

⁶*Reconstructive surgery, Karolinska University Hospital, Stockholm, Sweden*



⁷Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden

⁸Division of Dermatology and Venerology, Department of Medicine Solna, Karolinska Institutet and Unit of Dermatology and Venerology, Karolinska University Hospital, Solna, Sweden

⁹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, United States

151 Efficacy and adverse effects of oral Janus kinase inhibitor (JAKi) use in patients with lichen planopilaris: a retrospective case series and systematic review

Li-Chi Chen¹, Chino Ogbutor¹, Kristen Kelley¹, Maryanne Senna^{1,2}

¹Department of Dermatology, Lahey Hospital & Medical Center, Burlington, United States,

²Department of Dermatology, Harvard Medical School, Boston, United States

152 Investigating the role of the extracellular matrix to induce “pioneer melanoma cells”

Pauline Weinzettl¹, Wolfgang Weninger¹, Karin Pfisterer¹

¹Department of Dermatology, Medical University of Vienna, Vienna, Austria

153 Effectiveness of OR-101, a Next Generation Highly Selective JAK3 Inhibitor, in a Humanized Murine Model of Alopecia Areata

Amos Gilhar¹, Aviad Keren¹, Wadje Ahmad², Patricia Walker², Michael Howell², Fauad Hasan²

¹Technion, Haifa, Israel

²Ornivi, Irving, USA

154 Anti-inflammatory peptide alleviates dermatitis in an Atopic dermatitis mouse model

Seonghyang Sohn¹, Hasan Sayeed¹, Babita Rahar¹, Hye-Myung Ryu¹

¹Ajou University, Suwon, South Korea

155 T cell deficiency associated with downregulation of GPI-anchored proteins

Katja Knapp^{1,2}, Wolfgang Bauer¹, Ram Vinay Pandey¹, Thomas Hannich², Georg Stary^{1,2}

¹Department of Dermatology, Medical University of Vienna, Vienna, Austria

²CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

156 Increased risk of onset of cardiovascular diseases in vitiligo patients: a retrospective large-scale real-world based population study based on the US Collaborative Network

Alicja Fraczek², Agnieszka Owczarczyk-Saczonek², Diamant Thaçi¹, [Henner Zirpel](#)¹

¹*Institute And Comprehensive Center Inflammation Medicine, Univeristy Hospital Schleswig-Holstein, Lübeck, Lübeck, Germany*

²*Dermatology, Sexually Transmitted Diseases and Clinical Immunology, School of Medicine, University Warmia and Mazury in Olsztyn, Olsztyn, Poland*

157 Development of a new vitiligo mouse model based on mRNA vaccination and using a digital scoring system for skin depigmentation

Julien Perdoux¹, Raphael Thierry², Yeter Kolb¹, Ratiba Touil¹, Claire Refour¹, Celine Rauld¹, Jan Weiler³, Caitlin Hagen³, Michael Beverly³, Till Roehn¹, Thomas Calzascia¹, [Martin Schneider](#)¹

¹*Immunology - Novartis Institutes For Biomedical Research, Basel, Switzerland*

²*NX AI and Computational Sciences -Novartis Institutes of BioMedical Research, Basel, Switzerland*

³*NIBR Biologics Center - Novartis Institutes of BioMedical Research, Basel, Switzerland*

158 The keratin-associated protein epiplakin is down-regulated in psoriasis.

[Hannes Kühnreiber](#)^{1,2}, Corinne Drexler³, Johannes Griss¹, Hendrik Jan Ankersmit^{2,4}, Peter Fuchs³, Michael Mildner¹

¹*Department of Dermatology, Medical University of Vienna, Vienna, Austria*

²*Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria*

³*Max Perutz Labs, Department of Biochemistry and Cell Biology, University of Vienna, Vienna, Austria*

⁴*Aposcience AG, Vienna, Austria*

159 Regulation of T cell functions by cytoskeletal proteins in the melanoma tumor microenvironment

[Nikhila Harikummar](#)^{1,2}, Varun Sharma², Rene Platzer³, Lilliane Borik¹, Karin Pfisterer¹, Peter Petzelbauer¹, Jorg Menche^{2,4}, Christoph Hoeller¹, Loïc Dupré^{1,6}, Johannes Huppä³, Christoph Bock^{2,5}, Georg Stary^{1,2}

¹*Department of Dermatology, Medical University of Vienna, Vienna, Austria*

²*CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria*

³*Center for Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University of Vienna, Vienna, Austria*

⁴*Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Vienna, Austria*

⁵*Institute of Artificial Intelligence, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria*

⁶*Toulouse Institute for Infectious and Inflammatory Diseases (INFINITY), INSERM, CNRS, Toulouse III Paul Sabatier University, Toulouse, France*



- 160** Monocentric retrospective analysis of the dermatological care situation of hidradenitis suppurativa (HS) patients in urban and rural regions of Bavaria
Juliane Schrön¹, Tim Maisch¹, Mark Berneburg¹, Dennis Niebel¹
¹*Universitätsklinikum Regensburg, Klinik und Poliklinik für Dermatologie, Regensburg, Deutschland*
- 161** IL-17A and IL-17F in the pathogenesis of hidradenitis suppurativa: insights from early and chronic lesions
Andrew Skelton¹, Hudaa Gopee², Remi Okoye¹, Alex Ferecsko¹, Matthew Page¹, Stevan Shaw¹
¹*UCB Pharma, Slough, United Kingdom*
²*Newcastle University, Newcastle, United Kingdom*
- 162** Lesional B Cells differ between clinical subtypes of Bullous Pemphigoid
Sabina Gansberger¹, Wolfgang Bauer¹, Johannes Griss¹
¹*Department of Dermatology, Medical University of Vienna, Vienna, Austria*
- 163** Skin microbiome as predictor and pathogenesis mechanism for severe radiodermatitis in breast cancer patients
Claudia Hülpüsch^{1,2,3}, Avidan U. Neumann^{1,3,4}, Matthias Reiger^{1,2,4}, Julius C. Fischer⁵, Amedeo De Tomassi¹, Gertrud Hammel^{1,4}, Carina Gülzow^{1,2,3}, Megan Fleming², Hendrik Dapper⁵, Michael Mayinger⁵, Marco Vogel⁵, Christina Ertl⁵, Stephanie E. Combs^{5,6,7}, Claudia Traidl-Hoffmann^{1,2,3,4}, Kai J. Borm⁵
¹*Environmental Medicine, Faculty Of Medicine, University Of Augsburg, Augsburg, Germany*
²*Chair of Environmental Medicine, Technical University Munich, Augsburg, Germany*
³*CK CARE, Christine Kühne Center for Allergy Research and Education, Davos, Switzerland*
⁴*Institute of Environmental Medicine, Helmholtz Center Munich, Augsburg, Germany*
⁵*Department of Radiation Oncology, School of Medicine and Klinikum rechts der Isar, Technical University of Munich, Munich, Germany*
⁶*Germany Institute of Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, Munich, Germany*
⁷*German Consortium for Translational Cancer Research (dktk), Partner Site Munich, Munich, Germany*
- 164** Epigenetic and Transcriptional Profiling of PBMCs in Mild and Severe Alopecia Areata using Single-Cell RNA-Seq and ATAC-Seq
Jesus Gay-Mimbrera¹, Miguel Juan-Cencerrado², Irene Rivera-Ruiz², Pedro J Gómez-Arias², Eloisa Andújar-Pulido³, Macarena Aguilar-Luque¹, Mónica Pérez-Alegre³, Juan Ruano²
¹*Inflammatory Immune-Mediated Chronic Skin Diseases Laboratory, IMIBIC, Córdoba, Spain*
²*IMIBIC and Department of Dermatology, Reina Sofia University Hospital, Córdoba, Spain*
³*Genomic Core Facility, Andalusian Molecular Biology and Regenerative Medicine Center (CABIMER), CSIC-University of Seville-University Pablo de Olavide, Seville, Spain,*

165 Single-Cell RNA Sequencing Analysis Unveils Highly Active yet Diminished CD14+CD16- Circulating Monocytes, Independent of Alopecia Areata Severity

Jesús Gay-Mimbrera¹, Pedro J Gómez-Arias², Irene Rivera-Ruiz², Eloísa Andújar-Pulido³, Miguel Juan-Cencerrado², Macarena Aguilar-Luque¹, Mónica Pérez-Alegre³, Juan Ruano²

¹Inflammatory Immune-Mediated Chronic Skin Diseases Laboratory, IMIBIC, Córdoba, Spain

²IMIBIC and Department of Dermatology, Reina Sofía University Hospital, Córdoba, Spain

³Genomic Core Facility, Andalusian Molecular Biology and Regenerative Medicine Center (CABIMER), CSIC-University of Seville-University Pablo de Olavide, Seville, Spain,

166 Dynamic roles of mononuclear phagocytes in human graft-versus-host disease

Johanna Strobj^{1,2,3}, Laura Marie Gail^{1,3}, Laura Krecu¹, Shaista Madad^{2,4}, Lisa Kleiss^{1,3}, Luisa Unterluggauer¹, Philipp Wohlfarth⁵, Hanna Knaus⁵, Margit Mitterbauer⁵, Werner Rabitsch⁵, Muzlifah Haniffa^{2,6}, Georg Stary^{1,3}

¹Medical University Of Vienna, Department of Dermatology, Vienna, Austria

²Wellcome Sanger Institute, Hinxton, Cambridge, United Kingdom

³CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

⁴University of Cambridge, Cambridge, United Kingdom

⁵Medical University Of Vienna, Department of Internal Medicine I, Vienna, Austria

⁶Department of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne, United Kingdom

167 Epidermal GRK2 knockout triggers a hair loss phenotype with features resembling immune-mediated alopecias

Alejandro Asensio López¹, María Sanz-Flores¹, Jesús M Paramio², Ramón García-Escudero², Federico Mayor Menéndez jr¹, Catalina Ribas Núñez¹

¹Departamento de Biología Molecular and Centro de Biología Molecular "Severo Ochoa", CSIC-UAM, Madrid, Spain; Instituto de Investigación Sanitaria La Princesa, Madrid, Spain, CIBER Cardiovascular (CIBERCV), and Conexión Cáncer-CSIC, Madrid, Spain

²Molecular and Translational Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain. Biomedical Research Institute I+12, 12 de Octubre University Hospital, and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), MADRID, España



168 Effectivity of mTOR inhibition in cutaneous sarcoidosis

Anna Redl^{1,2}, Konstantin Doberer³, Luisa Unterluggauer¹, Christoph Krall⁴, Carolina Mayerhofer¹, Lisa Kleissl^{1,2}, Bärbel Reiningner¹, Victoria Stary⁵, Nina Zilla¹, Wolfgang Weninger¹, Thomas Weichhart⁶, Christoph Bock^{2,4}, Thomas Krausgruber^{2,4}, Georg Stary^{1,2}

¹Medical University of Vienna, Department of Dermatology, Vienna, Austria

²CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

³Medical University of Vienna, Department of Nephrology, Vienna, Austria

⁴Medical University of Vienna, Institute of Artificial Intelligence, Center for Medical Data Science, Vienna, Austria

⁵Medical University of Vienna, Department of General Surgery, Vienna, Austria

⁶Medical University of Vienna, Institute of Medical Genetics, Vienna, Austria

169 Unraveling the role of CD64+ DC population in melanoma

Janine Vierthaler¹, Florian Hornsteiner¹, Helen Strandt¹, Sophie Dieckmann¹, Christoph Tripp¹, Markus Kanduth², Sudhir Morla², Guido Wollmann², Patrizia Stoitzner¹

¹Department of Dermatology, Medical University of Innsbruck, Innsbruck, Austria

²Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria

170 Perceived stress can trigger psoriatic lesions in human skin in vivo, which can be suppressed by Aprepitant

Aviad Keren¹, Assaf A Zeltzer¹, Ralf Paus^{2,3,4}, Amos Gilhar¹

¹Skin Research Laboratory, Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

²Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, USA

³CUTANEON – Skin & Hair Innovations, Hamburg, Germany,

⁴Monasterium Laboratory, Münster, Germany

171 Deciphering dysfunctional regulatory T cells in atopic dermatitis

Hyun Je Kim^{1,5}, Seong-Jun Kang^{1,5}, Seon-Pil Jin², Jin-Mi Oh³, Emma Guttman-Yassky⁴, Chung-Gyu Park^{1,5}, Jeong Eun Kim⁶

¹Seoul National University College of Medicine, Seoul, South Korea

²Seoul National University Hospital, Seoul, South Korea

³Samsung Genome Institute, Samsung Medical Center, Seoul, South Korea

⁴Icahn School of Medicine at Mount Sinai, New York, USA

⁵PB Immune Therapeutics, Inc., Seoul, South Korea

⁶Hanyang University College of Medicine, Seoul, South Korea

172 Investigating IgE-reactive and non-IgE-reactive allergen effects on skin-resident antigen presenting cells of atopic dermatitis patients

David Samardzic¹, Matthias Wielscher¹, Pauline Weinzettl¹, Dörte Symmank¹, Lisa E. Shaw¹, Raffaella Campana², Huey-Jy Huang², Matthias Farlik¹, Christine Bangert¹, Susanne Vrtala², Rudolf Valenta², Karin Pfisterer¹, Wolfgang Weninger¹

¹Department of Dermatology / Medical University of Vienna, Vienna, Austria

²Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology / Medical University of Vienna, Vienna, Austria

173 Fluoxetine exerts anti-inflammatory effects on human epidermal keratinocytes, and suppresses their endothelin release

Kinga Fanni Tóth¹, Dorottya Ádám¹, József Arany¹, Yesid A. Ramirez², Tamás Bíró³, Jennifer I. Drake⁴, Alison O'Mahony⁴, Attila G. Szöllösi³, Ana Kilić⁵, Michael Soeberdt⁵, Christoph Abels⁵, Habil. Attila Oláh¹

¹Department of Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

²Faculty of Engineering, Design and Applied Sciences. School of Applied Sciences and Sustainable Industry, Department of Pharmaceutical and Chemical Sciences, Universidad Icesi, Cali, Colombia,

³Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary,

⁴Eurofins Discovery, St. Charles, USA

⁵Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany

174 AI's disruption of dermatology will remain highly heterogeneous: maximizing market competition, innovation, risk, and consumer choices

Luke Martin^{1,2,3}

¹The Royal Melbourne Hospital, Melbourne, Australia

²Wangaratta Hospital, Wangaratta, Australia

³Victorian Aboriginal Legal Service, Preston, Australia

175 Atopic dermatitis and Risk of Venous thromboembolism: A Systematic Review and Meta-analysis

Parkin Paramiraksa¹, Chonlawat Chaichan², Poramin Patthamalai³, Metavee Boonsiri³

¹Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand

²Department of Research and Medical Innovation, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand

³Dermatology Unit, Department of Internal Medicine, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Thailand



- 176** Hair eruption initiates adverse events of EGFR-targeted cancer therapy
Regina Jin¹, Jörg Klufa¹, Karoline Strobl¹, Lena Artner-Gent¹, Matthias Farlik², Maria Sibilia¹, Thomas Bauer¹
¹Center for Cancer Research, Comprehensive Cancer Center, Medical University Of Vienna, Vienna, Austria
²Department of Dermatology, Medical University of Vienna, Vienna, Austria
- 177** ALOX15B knockdown augments keratinocyte inflammation
Megan Palmer¹, Cluadia Bürger², Yvonne Benatzy¹, Bernhard Brüne¹
¹Institute of Biochemistry I, Goethe University Frankfurt, Frankfurt Am Main, Germany
²Department of Dermatology, Goethe University Frankfurt, Frankfurt am Main, Germany
- 178** Downregulation of MCPIP1 affects the non-coding RNA transcriptome in the squamous cell carcinoma of the skin
Agata Lichawska-Cieslar¹, Weronika Szukala¹, Gabriela Machaj², Guillem Ylla², Chiara Turco³, Giulia Fontemaggi³, Jolanta Jura¹
¹Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology, Department of General Biochemistry, Krakow, Poland
²Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology, Laboratory of Bioinformatics and Genome Biology, Krakow, Poland
³Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy
- 179** Assessment of Skin Vascularity Changes in Allergic Reactions using Ultrasound and Sensitive Doppler Flow Measurement
Rostyslav Bubnov^{1,2}, Liudmyla Petrenko², Mykola Spivak¹
¹Zabolotny institute of microbiology and virology, NAS of Ukraine, Kyiv, Ukraine
²Clinical hospital 'Pheophania', Kyiv, Ukraine
- 180** Guselkumab clinical super response is associated with faster normalization of blood and skin pathology: data from Phase IIIb GUIDE trial
Yanqing Chen¹, Julianty Angsana¹, Jocelyn Sendecki¹, Sarah Tabori², Nikolas Spindler², Sven Wegner², Robert Sabat³, Kerstin Wolk³, Andreas Pinter⁴, Peter Weisenseel⁵, Khusru Asadullah^{3,6}, Knut Schäkel⁷, Kilian Eyerich⁸, Brice Keyes¹, Monica WL Leung¹
¹Janssen R&D LLC, USA
²Janssen-Cilag GmbH, Germany
³Charité-Universitätsmedizin Berlin, Germany
⁴Uni. Hosp. Frankfurt am Main, Germany
⁵Dermatologikum Hamburg, Germany
⁶Dermatology Potsdam MVS, Potsdam, Germany
⁷Heidelberg Uni. Hosp., Germany
⁸Med. Center, Uni. Of Freiburg, Germany

181 Investigating the potential of repurposing diacerein for the treatment of cutaneous wounds in recessive dystrophic epidermolysis bullosa

Sonja Dorfer¹, Michael Ablinger¹, Monika Wimmer¹, Selma Ibrahimasic¹, Julia Illmer¹, Johann W. Bauer^{1,2}, Roland Zauner¹, Verena Wally¹

¹*EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria*

²*Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University, Salzburg, Austria*

182 Chronic ER stress promotes cGAS/mtDNA-induced autoimmunity via ATF6 in myotonic dystrophy type 2

Sarah Rösing¹, Fabian Ullrich^{2,3}, Susann Meisterfeld¹, Franziska Schmidt¹, Laura Mlitzko¹, Marijana Croon¹⁰, Nadia Eberl¹, Martin Schlee², Daniel Hilbig⁴, Ulrike Reuner⁵, Alexander Rapp⁸, Peter Mirtschink⁶, Stephan Drukewitz⁷, Thomas Zillinger², Stefan Beissert¹, Katrin Paeschke⁴, Gunther Hartmann², Alexandra Trifunovic¹⁰, Eva Bartok^{2,3,9}, Claudia Günther¹

¹*TU Dresden, Faculty Of Medicine, University Hospital, Dep. Of Dermatology, Dresden, Germany*

²*Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany*

³*Institute of Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany*

⁴*Department of Oncology, Hematology, Rheumatology and Immune-Oncology, University Hospital Bonn, Bonn, Germany*

⁵*Department of Neurology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany*

⁶*Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine, TU Dresden, Dresden, Germany*

⁷*Core Unit for Molecular Tumor Diagnostics (CMTD), National Center for Tumor Diseases (NCT), Partner Site Dresden, Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany*

⁸*Department of Biology, Cell biology and Epigenetic, Technical University of Darmstadt, Darmstadt, Germany*

⁹*Unit of Experimental Immunology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium*

¹⁰*Institute for Mitochondrial Diseases and Aging, Faculty of Medicine, CECAD Research Center, Cologne, Germany*



- 183** Litiflimab modulates Type I interferon biomarkers in patients with cutaneous lupus erythematosus: Result of the LILAC Part B Phase 2 study
Victoria Werth¹, Richard Furie², [Joseph Merola](#)³, Eric Milliman⁴, Kyle Ferber⁴, Fergal Casey⁴, Roland Brown⁴, Denitza Raitcheva⁴, Jad Zoghbi⁴, Danielle Graham⁴, George Kong⁴, Youmna Lahoud⁴, Nathalie Franchimont⁵, Catherine Barbey⁶
¹University of Pennsylvania, Philadelphia, USA
²Northwell Health, Great Neck, USA
³Harvard Medical School, Brigham and Women's Hospital, Boston, USA
⁴Biogen, Cambridge, USA
⁵Former employee of Biogen, Cambridge, USA
⁶Biogen, Switzerland
- 184** Aggregation of infectious skin ulcer cases - does metagenomic sequencing shed light on diagnosis?
[Bin Yin](#)¹, Li Zhang¹, Di Wang¹, Sirui Chen¹, Fen Li¹
¹Chengdu Second Hospital, Chengdu, China
- 185** Regulatory $\gamma\delta$ T cells protect human scalp hair follicles from alopecia areata in vivo
Aviad Keren¹, Nyra Goldstein¹, Marta Bertolini⁵, Riad Kassem³, Ralf Paus^{2,4,5}, [Amos Gilhar](#)¹
¹Skin Research Laboratory, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
²Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, USA
³Dermatology department, Sheba medical center, Sackler school of medicine, Tel Aviv University, Tel Aviv, Israel
⁴CUTANEON - Skin & Hair Innovations, Hamburg, Germany
⁵Monasterium Laboratory, Münster, Germany
- 186** Real-world clinical characteristics and treatment practices in generalized pustular psoriasis as seen in a chart review (SCRIPTOR)
Denis Jullien¹, Azura Mohd Affandi², Tang Jyh Jong³, Latha Selvarajah⁴, Hamida Turki⁵, Laurent Misery⁶, [Thomas Zimmermann](#)⁷, Patrick Hofmann⁷, Pubalan Muniandy⁸, Tan Wooi Chiang⁹, Enna Bahloul⁵
¹Hospices Civils de Lyon, Édouard Herriot Hospital, Department of Dermatology, Lyon, France
²Hospital Kuala Lumpur, Dermatology, Kuala Lumpur, Malaysia
³Hospital Raja Permaisuri Bainun, Ipoh, Dermatology, Perak, Malaysia
⁴Hospital Sultan ismail Johor Bahru, Malaysia, Dermatology, Bahru, Malaysia
⁵Hedi Chaker Hospital, University of Sfax, Department of Dermatology, Sfax, Tunisia
⁶University Hospital of Brest, Department of Dermatology, Brest, France
⁷Boehringer Ingelheim, Ingelheim, Germany
⁸Sarawak General Hospital, Kuching, Department of Dermatology, Sarawak, Malaysia
⁹Hospital Pulau Pinang, Department of Dermatology, Penang, Malaysia

187 Bimekizumab treatment in psoriasis patients: A mechanistic understanding of the durable clinical response

Ioana Cutcutache¹, Andrew Skelton¹, Athanassios Koliavas^{2,3}, Joe Rastrick¹,

James G. Krueger⁴, Matthew Page¹, Stevan Shaw¹

¹UCB Pharma, Slough, United Kingdom

²UCB Pharma, Brussels, Belgium

³Université Libre de Bruxelles, Brussels, Belgium

⁴Centre for Clinical and Translational Science, The Rockefeller University, New York, USA

188 Laboratory Safety of Long-Term Dupilumab Treatment in a 5-Year Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis

Lisa A. Beck¹, Robert Bissonnette², Mette Deleuran³, Takeshi Nakahara⁴, Ryszard Galus⁵,

Faisal A. Khokhar⁶, Anna Coleman⁷, Guy Gherardi⁸, Zhen Chen⁶, Elena Avetisova⁶, Ariane

Dubost-Brama⁹, Arsalan Shabbir⁶

¹University of Rochester Medical Center, Rochester, USA

²Innovaderm Research, Montreal, Canada

³Aarhus University Hospital, Aarhus, Denmark

⁴Kyushu University, Fukuoka, Japan

⁵Medical University of Warsaw, Warsaw, Poland

⁶Regeneron Pharmaceuticals Inc., Tarrytown, USA

⁷Regeneron Pharmaceuticals Inc., Dublin, Ireland

⁸Sanofi, Reading, UK

⁹Sanofi, Chilly-Mazarin, France

189 Dupilumab Treatment for up to 5 Years Improves Clinical Signs Across all Anatomical Regions in Adults With Moderate-to-Severe Atopic Dermatitis

Lisa A. Beck¹, Robert Bissonnette², Mette Deleuran³, Takeshi Nakahara⁴, Ryszard Galus⁵,

Zhen Chen⁶, Elena Avetisova⁶, Ariane Dubost-Brama⁷, Arsalan Shabbir⁶

¹University of Rochester Medical Center, Rochester, USA

²Innovaderm Research, Montreal, Canada

³Aarhus University Hospital, Aarhus, Denmark

⁴Kyushu University, Fukuoka, Japan

⁵Medical University of Warsaw, Warsaw, Poland

⁶Regeneron Pharmaceuticals Inc., Tarrytown, USA

⁷Sanofi, Chilly-Mazarin, France

190 Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis

Emma Guttman-Yassky¹, Angela Okragly², Zhe Sun², Laura Rebeca Mena², Nathan Hahn²,

Brian J. Nickoloff², Kimberly Siu², Gaia Gallo², Eric Wolf², Kilian Eyerich³, Monica Aparici⁴,

Robert J. Benschop²

¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA

²Eli Lilly and Company, Indianapolis, USA

³Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany

⁴Almirall S.A., Barcelona, Spain



- 191** **Lebrikizumab treatment results in rapid improvement of atopic dermatitis disease cytokines and pathways**
Emma Guttman-Yassky¹, Angela Okragly², Zhe Sun³, Brian J. Nickoloff², Christoph Preuss², Chitra R. Natalie², Gaia Gallo², Eric Wolf², Kilian Eyerich³, Monica Aparici⁴, Robert J. Benschop²
¹*Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA*
²*Eli Lilly and Company, Indianapolis, USA*
³*Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany*
⁴*Almirall S.A., Barcelona, Spain*
- 192** **Assessing treatment effect of baricitinib in atopic dermatitis using digital endpoints derived from actigraphy data: nocturnal scratch and sleep disturbance**
Ju Ji¹, Hui Zhang¹, Brian Winger¹, Tracy Cardillo¹, Lisa Cirri¹, Andrew Buchanan¹, Jonathan Silverberg², Amy Paller³, Emma Guttman-Yassky⁴, Sreekumar Pillai¹
¹*Eli Lilly and Company, Indianapolis, United States*
²*George Washington University School of Medicine, Washington DC, United States*
³*Feinberg School of Medicine, Northwestern University, Chicago, United States*
⁴*Mount Sinai, New York City, United States*
- 193** **Cytokines, chemokines, proteases, and protease inhibitors distinguish the uninvolved skin of patients with mild and severe psoriasis**
Renáta Bozó^{1,2}, Barbara Ambrus¹, Lili Borbála Flink^{1,2}, Ameneh Ghaffarinia², Balázs Koncz³, Lajos Kemény^{2,1,4}, Zsuzsanna Bata-Csörgő^{1,2,4}
¹*University Of Szeged, Albert Szent-Györgyi Medical School, Department Of Dermatology And Allergology, Szeged, Hungary*
²*HCEMM-USZ Skin Research Group, University of Szeged, Szeged, Hungary*
³*ELKH Biological Research Centre, Eötvös Loránd Research Network, Szeged, Hungary*
⁴*HUN-REN-SZTE Dermatological Research Group, Szeged, Hungary*
- 194** **Effect of Ruxolitinib Cream on Biomarkers of Atopic Dermatitis**
Susan Smith¹, Angelina Volkova¹, Yeriel Estrada², Joel Correa da Rosa², Etienne Saint-Cyr Proulx³, Haq Nawaz¹, Philippa Halden¹, Emma Guttman-Yassky²
¹*Incyte Corporation, Wilmington, United States*
²*Icahn School of Medicine at Mount Sinai, New York, United States*
³*Innovaderm Research, Montréal, Canada*
- 195** **Development of a machine learning tool for descriptive analysis of the distribution of T cells in healthy human skin**
Trine Schoenfeldt¹, Liv Eidsmo^{1,2}
¹*Leo Foundation Skin Immunology Research Center, University Of Copenhagen, Copenhagen, Denmark*
²*Karolinska Institute, Stockholm, Sweden*

- 196 Squamous Cell Carcinoma in patients with Recessive Dystrophic Epidermolysis Bullosa is associated with dysregulated T cell function**
 Anshu Sharma¹, Giorgia Nasi¹, Sarra Zaafour¹, Suraj R Varkhandede¹, Maria M Klicznik¹, Katharina Umundum¹, Michael Lew¹, Amalia Sophianidis¹, Leonie C Schöftner¹, Alina C Gerstenberger¹, Josefina Pinon Hofbauer², Christina Guttman-Gruber², Nikolaus Fortelny¹, Verena Wally², Daniel J Campbell³, Iris K Gratz^{1,2,3}
¹University of Salzburg, Salzburg, Austria
²EB House Austria, Salzburg, Austria
³Benaroya Research Institute, Seattle, USA
- 197 Spatial analysis of anti-lymphoma immune cells in cutaneous T cell lymphoma**
 Julia Nenonen¹, Mengmeng Xiang¹, Marcus Ehrström², Liv Eidsmo³, Hanna Brauner¹
¹Karolinska Institutet, Stockholm, Sweden
²Karolinska University Hospital, Stockholm, Sweden
³University of Copenhagen, Copenhagen, Denmark
- 198 The involvement of Immunogenic Cell Death in Extracorporeal Photopheresis**
Angelika Lackner¹, Teresa Burner¹, Ahmed El-Gazzar³, Veronika Buxhofer-Ausch^{2,3}, Marija Geroldinger-Simic⁴, Emmanuella Guenova⁵, Susanne Kimeswenger¹, Wolfram Hoetzenecker^{1,6}
¹Department of Dermatology and Venerology, JKU Linz, Linz, Austria
²Department of Internal Medicine I with Hematology, Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria
³Medical Faculty, JKU Linz, Linz, Austria
⁴Department of Dermatology and Venerology, Ordensklinikum Linz Elisabethinen, Linz, Austria
⁵Department of Dermatology, University of Lausanne and Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
⁶Department of Dermatology and Venerology, Kepler University Hospital Linz, Linz, Austria
- 199 Large-scale bioinformatic analysis reveals cancer specific B cell responses with opposing effects on survival**
Inigo Oyarzun¹, Sabina Gansberger¹, Alexander Grentner¹, Johannes Griss¹
¹Department of Dermatology, Medical University Of Vienna, Vienna, Austria
- 200 Detection of native, activated Notch receptors in normal human apocrine-bearing skin and in hidradenitis suppurativa**
Siri Hansen Stabell^{1,2,3}, Anastasia Renzi³, Hogne Røed Nilsen³, Olaf Harald Antonsen², Johanna Hol Fosse³, Guttorm Haraldsen^{1,3}, Olav Sundnes^{1,2}
¹Institute of clinical medicine, University of Oslo, Oslo, Norway
²Department of Dermatology, Oslo University Hospital, Oslo, Norway
³Department of Pathology, Oslo University Hospital, Oslo, Norway



201 Bone Safety Data in Adolescents With Moderate-To-Severe Atopic Dermatitis Treated With Abrocitinib: Interim Results From the JADE EXTEND MRI Substudy

Jacek Zdybski¹, Andreas Wollenberg², Carsten Flohr³, Patrick M. Brunner⁴, Wolfgang Högl⁵, Alexander Egeberg⁶, Alan D. Irvine⁷, Haiyun Fan⁸, Pinaki Biswas⁹, Zaher Radi¹⁰, Saleem A. Farooqui¹¹, Herwig Koppensteiner¹², Sarah P. Sherlock¹⁰, Gary Chan¹³

¹Dermedic Jacek Zdybski, Ostrowiec Świętokrzyski, Poland

²University Hospital Augsburg, Augsburg, Germany and Ludwig Maximilian University, Munich, Germany

³St John's Institute of Dermatology and Guy's and St Thomas' NHS Foundation Trust, King's College London, United Kingdom

⁴Icahn School of Medicine at Mount Sinai, New York, USA

⁵Johannes Kepler University Linz, Linz, Austria

⁶Bispebjerg University Hospital, University of Copenhagen, Copenhagen, Denmark

⁷Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland

⁸Pfizer Inc., Collegeville, USA

⁹Pfizer Inc., New York, USA

¹⁰Pfizer Inc., Cambridge, USA

¹¹Pfizer Ltd., Sandwich, United Kingdom

¹²Pfizer Corporation Austria GmbH, Vienna, Austria

¹³Pfizer Inc., Groton, USA

202 Increased circulating IL-17+ TRM are associated with Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa

Anshu Sharma¹, Sarra Zaafour¹, Suraj R Varkhande¹, Maria M Klicznik¹, Giorgia Nasi¹, Katharina Umundum¹, Michael Lew¹, Amalia Sophianidis¹, Leonie C Schöftner¹, Alina Gerstenberger¹, Eva M Murauer², Josefina Pinon Hofbauer², Christina Guttman-Gruber², Nikolaus Fortelny¹, Verena Wally², Daniel J Campbell³, Iris K Gratz^{1,2,3}

¹Department of Biosciences and Medical Biology, University Of Salzburg, Salzburg, Austria

²EB House Austria, Department of Dermatology, University Hospital of the Paracelsus Medical University, Salzburg, Austria

³Benaroya Research Institute, Seattle, USA

203 Immune-mesenchymal crosstalk contribute to the expansion of autoreactive plasma cells in the tertiary lymphoid structures in Hidradenitis Suppurativa

Wei-wen Yu¹, Joy Barrett¹, Meng-ju Lin¹, Meaghan Marohn¹, Joseph Devlin¹, Alberto Herrera¹, Juliana Remark¹, James Krueger², Kelly Ruggles¹, Sergei Korolov¹, Ernest Chiu¹, Catherine Lu¹

¹New York University School of Medicine, New York, United States

²Rockefeller University, New York, United States

- 204 Abrocitinib Reverses the Altered Immune and Skin Barrier Phenotype in Skin Biopsies From Patients With Moderate-To-Severe Atopic Dermatitis**
 Ester Del Duca¹, Emma Guttmann-Yassky¹, Joel Correa Da Rosa¹, Yerieli Estrada¹, Madeline Kim¹, Paola Facheris², Pedro Jesus Gomez-Arias³, Karen Page⁴, Erman Güler⁵, Dan Xu⁶, Allshine Chen⁷, Gary Chan⁷, Urs Kerkmann⁸
¹Icahn School of Medicine at Mount Sinai, New York, USA
²IRCCS Humanitas Research Hospital, Rozzano, Italy
³Reina Sofia University Hospital, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain
⁴Pfizer Inc., Cambridge, USA
⁵Pfizer Inc., Istanbul, Turkey
⁶Pfizer Inc., San Diego, USA
⁷Pfizer Inc., Groton, USA
⁸Pfizer Pharma GmbH, Berlin, Germany
- 205 Tape Strip Genomic Profiling of Lesional and Nonlesional Atopic Dermatitis Skin Identifies Early and Progressive Normalization Following Treatment With Abrocitinib**
 Madeline Kim¹, Emma Guttmann-Yassky¹, Joel Correa Da Rosa¹, Ester Del Duca¹, Yerieli Estrada¹, Paola Facheris², Pedro Jesus Gomez-Arias³, Karen Page⁴, Erman Güler⁵, Dan Xu⁶, Allshine Chen⁷, Gary Chan⁷, Urs Kerkmann⁸
¹Icahn School Of Medicine at Mount Sinai, New York, USA
²IRCCS Humanitas Research Hospital, Rozzano, Italy
³Reina Sofia University Hospital, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain
⁴Pfizer Inc., Cambridge, USA
⁵Pfizer Inc., Istanbul, Turkey
⁶Pfizer Inc., San Diego, USA
⁷Pfizer Inc., Groton, USA
⁸Pfizer Pharma GmbH, Berlin, Germany
- 206 SAR445399 - an anti-IL-1R3 monoclonal antibody that blocks IL-1, IL-33 and IL-36 cytokine pathways for dermatologic diseases**
 Winnie Tung¹, Christian Asbrand², Ziyu Li², Hanno Sjuts², Heming Xing¹, Luciana Zimmermann², Matthias Ozog², Davide Lucchesi³, Caroline Dreis², Kyung In Kim¹, Ben Lin¹
¹Sanofi, Cambridge, United States
²Sanofi, Frankfurt, Germany
³Sanofi, UK



207 Spatial proteomic and transcriptomic profiling of lichen planus reveals a unique inflammatory architecture

James Garritano¹, Michal Kidacki², Christina Cho³, Francesc Lopez-Giraldez^{4,5}, William Damsky^{1,2}, Lieping Chen^{2,3,6}, [Matthew Vesely](#)¹

¹Department of Pathology, Yale University, New Haven, United States

²Department of Dermatology, Yale University, New Haven, United States

³Department of Immunobiology, Yale University, New Haven, United States

⁴Department of Genetics, Yale University, New Haven, United States

⁵Yale Center for Genome Analysis, New Haven, United States

⁶Department of Medicine (Medical Oncology), Yale University, New Haven, United States

208 IL-4 And IL-13 Drive Distinct And Overlapping Disease-Associated Signatures In Cell Types Relevant to Atopic Dermatitis

[Subhashini Srivatsan](#)¹, Brianna Buonagurio¹, Kirsten Nagashima¹, Seblewongel Asrat¹, Wei Keat Lim¹, Audrey Le Floch¹, Michael Garcia¹, Daria Zamolodchikov¹, Dharani Ajithdoss¹, Nicole Alessandri-Haber¹, Andrew Murphy¹, Matthew Sleeman¹, Jamie Orengo¹

¹Regeneron Pharmaceuticals, Inc., Tarrytown, United States

209 Biomarkers of subcutaneous tissue antibiotic penetration in sepsis

[Maria Sanz Codina](#)¹, Hartmuth Nowak², Markus Zeitlinger¹

¹Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

²Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus Bochum, Bochum, Germany

210 THE P-RPS6-ZONE DELINATES WOUNDING RESPONSE AND THE HEALING PROCESS.

[Helene Dworak](#)^{1,2,3}, Nadja Ring^{1,2,3}, Barbara Bachmann^{1,2,3}, Barbara Schädl^{2,3,4},

Karla Valdivieso^{1,2,3,5}, Heinz Redl^{1,2,3}, Mikolaj Ogrodnik^{1,2,3}

¹Ludwig Boltzmann Research Group Senescence and Healing of Wounds, Vienna, Austria

²Ludwig Boltzmann Institute for Traumatology, The Research Centre in Cooperation with AUVA, Vienna, Austria

³Austrian Cluster for Tissue Regeneration, Vienna, Austria

⁴University Clinic of Dentistry, Medical University of Vienna, Vienna, Austria

⁵Institute of Molecular Biotechnology, Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria

211 Abscopal effect in image guided pulsed bioenergy treatments

[Robert Bard](#)¹, Orit Markowitz¹, Giovanni Pellacani¹, Sandra Schuh¹, Noelle Cutter¹,

Charles Simone¹, Jane Yoo¹

¹AngioFoundation (501c3), New York, United States

²University of Rome, Rome, Italy

212 An Un-Masking Cream: Discovery of T-Cell Dyscrasia after Treatment with Tapinarof

Emily Gordon¹, Oluwaseyi Adeuyan¹, Megan Trager², Celine Schreidah¹, Brigit Lapolla², Lauren Fahmy¹, Karen Wesson³, Cynthia Magro⁴, Larisa Geskin²

¹*Columbia University Vagelos College of Physicians and Surgeons, New York, United States*

²*Department of Dermatology, Columbia University Irving Medical Center, New York, United States*

³*Wesson Dermatology, New York, United States*

⁴*Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, United States*

213 Overlapping Confusion: Overlap of CTCL with Lichen Sclerosus et Atrophicus and Morphea

Emily Gordon¹, Oluwaseyi Adeuyan¹, Brigit Lapolla², Megan Trager², Celine Schreidah¹, Lauren Fahmy¹, Larisa Geskin²

¹*Columbia University Vagelos College of Physicians and Surgeons, New York, United States*

²*Department of Dermatology, Columbia University Irving Medical Center, New York, United States,*

214 Angiolymphoid Hyperplasia with Eosinophilia and Kimura Disease: A Case of Clinical and Histopathological Discrepancy and Response to Dupilumab

Brigit Lapolla¹, Emily Gordon², Lauren Fahmy², Celine Schreidah², Oluwaseyi Adeuyan², Cynthia Magro³, Larisa Geskin¹

¹*Department of Dermatology, Columbia University Irving Medical Center, New York, United States,*

²*Columbia University Vagelos College of Physicians and Surgeons, New York, United States*

³*Division of Dermatopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, United States*

215 Cutaneous lupus single cell analyses reveal critical type I interferon mediated reprogramming of skin stroma

Jeff Gehlhausen¹, Emily Baker¹, Sarika Ramachandran¹, Akiko Iwasaki^{1,2,3}

¹*Yale Dermatology, New Haven, United States*

²*Yale Department of Immunobiology, New Haven, United States*

³*Howard Hughes Medical Institute, New Haven, United States*



- 216 Human epidermal Langerhans cells emigrate and induce a tolerogenic immune response in response to tick feeding and tick-borne pathogens**
Lisa Kleissl^{1,2}, Johanna Strobl^{1,2}, Michiel Wijnveld³, Sophie Müller¹, Sophie Weninger¹, Aglaja Kopf^{1,2}, Laura Marie Gail^{1,2}, Clement Staud⁴, Mateusz Markowicz⁵, Hannes Stockinger³, Georg Stary^{1,2}
¹Medical University of Vienna/ Department of Dermatology, Vienna, Austria
²CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
³Institute for Hygiene and Applied Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
⁴Department of Plastic and Reconstructive Surgery, Medical University of Vienna, Vienna, Austria
⁵Austrian Agency for Food and Health Safety (AGES), Vienna, Austria
- 218 Staphylococcus aureus-specific skin resident memory T cells protect against bacteria colonization but exacerbate atopic dermatitis-like flares in mice**
Camille Braun¹, Cédric Badiou¹, Aurélie Guironnet-Paquet¹, Masashi Iwata², Vanina Lenief¹, Amandine Mosnier¹, Charlotte Beauclair¹, Emilie Renucci¹, Pauline Bouchon¹, Roxane Cuzin¹, Yoann Briand¹, Vijaykumar Patra¹, Sabine Patot¹, Tiffany Scharschmidt³, Willem van Wamel⁴, Nicole Lemmens⁴, Saeko Nakajima², François Vandenesch¹, Jean-François Nicolas¹, Gérard Lina¹, Audrey Nosbaum¹, Marc Vocanson¹
¹Centre International De Recherche En Infectiologie, Lyon, France
²University Graduate School of Medicine, Kyoto, Japan
³University of California, San Francisco, USA
⁴Erasmus Medical Center, Rotterdam, Netherlands
- 219 Single-cell dissection of tissue-immune regulation in cutaneous acute Graft-versus-Host Disease**
Laura Marie Gail^{1,2}, Florian Deckert³, Luisa Unterluggauer², Ruth Dingelmaier-Hovorka², Johanna Strobl², Anna Redl², Lisa Ellen Shaw², Matthias Farlik², Werner Rabitsch³, Georg Stary^{1,2}
¹CeMM Research Center for Molecular Medicine, Austrian Academy of Sciences, Vienna, Austria
²Department of Dermatology, Medical University Of Vienna, Vienna, Austria
³Department of Medicine I, Medical University Of Vienna, Vienna, Austria

220 Detection of skin allergy biomarkers for point-of-care diagnosis of contact dermatitis

Marine-Alexia Lefevre^{1,2}, Audrey Nosbaum^{1,3}, Amandine Mosnier¹, Vanina Lenief¹, Samuel Salque¹, Marie Pichot¹, Léa Maheux¹, Léa Bertolotti¹, Florence Hacard^{1,3}, Céline Graveriau⁴, Pascale Zukervar⁴, Anne-Laure Breton Guitarian⁴, Fanny Boisleve⁵, Michèle Elbaz⁵, Jean-François Nicolas^{1,3}, [Marc Vocanson](#)¹

¹Centre International De Recherche En Infectiologie, Lyon, France

²Centre Hospitalier Universitaire de Saint-Etienne, Saint-Priest-en-Jarez, France

³Centre Hospitalier Lyon-Sud, France

⁴Private Dermatology Practice, Lyon, France

⁵Chanel, France

221 Extracellular granzyme B drives immunopathology by compromising epithelial barrier integrity during genital Herpes Simplex Virus-2 infections

[Ying Shiang Lim](#)^{1,2}, Haina Shin^{2,3}, Aisha Lee², David Granville⁴, John Common¹

¹A*STAR Skin Research Labs (ASRL), Singapore, Singapore

²Washington University in St. Louis, St. Louis, United States of America

³Bill & Melinda Gates Foundation, Seattle, United States of America

⁴University of British Columbia, Vancouver, Canada

222 New Perspectives on Immune Checkpoint Inhibitor-Induced Vitiligo-like Depigmentation in Melanoma: A Comparative Study with Classical Vitiligo and Healthy Skin

[M. Milad Amerj](#)^{1,2,3}, Reihane Ziadlou^{1,2,3}, Anna White^{1,2,3}, Nick Li^{1,2,3}, Nicola Herman¹, Marie Charlotte Brueggen^{1,2,3}

¹University Hospital Zurich, Zürich, Switzerland

²University of Zurich, Zürich, Switzerland

³Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland

223 CD8+ T cells could be crucial for long-term tolerance in patients undergoing venom immunotherapy

[Andrea Teufelberger](#)¹, Urban Cerpès^{1,2}, Andrada-Renata Dan^{1,2}, Danijela Bokanovic^{1,2}, Verena Cötze², Regina Fink-Puches^{1,2}, Birger Kränke^{1,2}, Peter Wolf^{1,2}

¹Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria

²University Hospital Graz, Graz, Austria

224 Corynebacterium diphtheriae activates ribotoxic stress and NLRP1 inflammasome-driven pyroptosis in a model of cutaneous diphtheria

[John Common](#)^{1,3}, Kim Robinson^{1,2}, Gee Ann Toh², Stephen Wearne¹, Pritisha Rozario², Franklin Zhong^{2,3}

¹A*STAR Skin Research Labs (A*SRL), Republic of Singapore

²Lee Kong Chian School of Medicine, Nanyang Technological University, Republic of Singapore

³Skin Research Institute of Singapore (SRIS), Republic of Singapore



225 Interleukin-1 β licenses interleukin-26 to potentiate type 2 skin inflammation

Katharina Bier¹, Zuzana Senajova¹, Fanny Henrion¹, Yichen Wang¹, Sandro Bruno¹, Celine Rauld¹, Lisa Christina Hörmann¹, Carmen Barske¹, Corinne Delucis-Bronne¹, Sebastian Bergling¹, Marc Altorfer¹, Jasmin Hägele¹, Judith Knehr¹, Tobias Junt¹, Ben Roediger¹, Till Röhn¹, Frank Kolbinger¹

¹Novartis Institutes For Biomedical Research, Basel, Switzerland

226 Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells

Christine Bangert², Natalia Alkon², Sumanth Chennareddy¹, Madgalena Pilz², John Ruggiero¹, Emry Cohenour¹, Constanze Jonak², Johannes Griss², Patrick Brunner¹

¹Icahn School of Medicine at Mount Sinai, New York, United States

²Medical University of Vienna, Vienna, Austria

227 Efficacy and safety of amltelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis (AD): 24-week results from a Phase 2b trial (STREAM-AD)

Stephan Weidinger¹, Andrew Blauvelt², Kim Papp³, Adam Reich⁴, Chih-Hung Lee⁵, Margitta Worm⁶, Charles Lynde⁷, Yoko Kataoka⁸, Peter Foley⁹, Christine Weber¹⁰, Wanling Wong¹¹, Natalie Rynkiewicz¹², Karl Yen¹³, John T. O'Malley¹⁴, Charlotte Bernigaud¹⁰

¹Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany

²Oregon Medical Research Center, Portland, United States

³Alliance Clinical Trials and Probitry Medical Research, Waterloo, Canada and The University of Toronto, Toronto, Canada

⁴Department of Dermatology, University of Rzeszow, Rzeszow, Poland

⁵Department of Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

⁶Department of Dermatology and Allergology, University Medical Center Berlin, Berlin, Germany

⁷University of Toronto, Markham, Canada

⁸Osaka Habikino Medical Center, Habikino, Japan

⁹Skin Health Institute, Carlton, Australia

¹⁰Sanofi, Paris, France

¹¹Sanofi, Bridgewater, United States

¹²Sanofi, Cambridge, United Kingdom

¹³Sanofi, Rotkreuz, Switzerland

¹⁴Sanofi, Cambridge, United States

228 What phenotypes have been identified in patients with Hidradenitis Suppurativa? A Critically Appraised Topic.

Adriana Ioannou¹, Emma McMullen², David Fitzgerald², Zenas Z.N. Yiu^{1,2}

¹University Of Manchester, Manchester, United Kingdom

²Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom

229 Comparative immune profiling of four autoimmune skin diseases identifies a mixed type-I and type-II interferon response as a unique inflammatory signature in skin dermatomyositis.

Khashayar Afshari¹, Yuqing Wang¹, Nazgol-Sadat Haddadi¹, Carolina Salomão Lopes¹, Elizabeth MacDonald¹, Jane Chuprin¹, Shany Sherman¹, Jillian Richmond¹, Ruth Ann Vleugels², John E Harris¹, Manuel Garber¹, Mehdi Rashighi¹

¹UMass Chan Medical School, Worcester, United States

²Harvard Medical School, Boston, United States

230 Immunosuppression causes dynamic changes in expression QTLs in psoriatic skin

Laura Cooney², Qian Xiao¹, Joseph Mears¹, Aparna Nathan¹, Kazuyoshi Ishigaki¹, Yuriy Baglaenko¹, Noha Lim², Kristina Harris², Mark Anderson², David Fox⁴, Dawn Smilek², James G. Krueger³, Soumya Raychaudhuri¹

¹Brigham and Women's Hospital, Harvard Medical School, and Broad Institute of MIT, Boston, USA

²Immune Tolerance Network, University of California San Francisco, San Francisco, USA

³Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA

⁴Division of Rheumatology, Department of Internal Medicine and Clinical Autoimmunity Center of Excellence, University of Michigan, Ann Arbor, United States

231 Non-lesional type 2 and type 17/22 immune activation precedes lesional type 1-associated inflammation in skin of vitiligo patients

Patrick M. Brunner¹, Ester Del Duca¹, Meredith Manson¹, Jesus Gay-Mimbrera², Pedro Gómez-Arias², Eden David¹, Camille Rothenberg Lausell¹, Ruano Ruiz Juan², Emma Guttman-Yassky¹

¹Department of Dermatology, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, United States

²Department of Dermatology, IMIBIC/Reina Sofia University Hospital, University of Córdoba, Spain

232 Single-cell RNA sequencing characterization of primary cutaneous B-cell lymphomas with their systemic counterparts

Johannes Griss¹, Sabina Gansberger¹, Inigo Oyarzun¹, Wolfgang Weninger¹, Werner Dolak², Matthias Farlik¹, Constanze Jonak¹, Patrick Brunner³

¹Department of Dermatology, Medical University of Vienna, Vienna, Austria

²Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

³Department of Dermatology, Icahn School of Medicine at Mount Sinai, USA



- 233 Mechanisms of type I interferon-mediated UVB sensitivity in human keratinocytes**
Nazgol Haddadi¹, Khashayar Afshari¹, Yuqing Wang¹, Jane Chuprin¹, Elizabeth MacDonald¹, Shanny Sherman-Bergman¹, Manuel Garber¹, Ruth-Ann Vleugels², Megan Orzalli¹, Mehdi Rashighi¹
¹Umass Chan Medical School, Worcester, United States
²Harvard Medical School, Boston, United States
- 234 Single-cell RNA sequencing reveals crosstalk between T cells and endothelial cells in a patient with intravascular T-cell lymphoma**
Stephan Traidl², Mehmet Fatih Atak¹, Wolfgang Bauer³, Katharina Rindler³, Thomas Werfel², Constanze Jonak³, Patrick Brunner¹
¹Icahn School of Medicine at Mount Sinai, New York, United States
²Hannover Medical School, Hannover, Germany
³Medical University of Vienna, Vienna, Austria
- 235 Cellular and molecular profiling of early-stage mycosis fungoides in comparison to parapsoriasis and atopic dermatitis reveals disease-specific markers**
Natalia Alkon², Sumanth Chennareddy¹, John Ruggiero¹, Emry Cohenour¹, Christine Bangert², Wolfgang Bauer², Johannes Griss², Constanze Jonak², Patrick Brunner¹
¹Icahn School of Medicine at Mount Sinai, New York, United States
²Medical University of Vienna, Vienna, Austria
- 236 Disrupted keratinocyte differentiation and increased chemokine and antimicrobial peptide expression in palmoplantar keratoderma due to keratin 9 mutation**
Daniela Ortner-Tobider¹, Thomas Trafoier¹, Michael Mildner², Christine Heufler¹, Matthias Schmuth¹
¹Dermatology, Medical University Innsbruck, Innsbruck, Austria
²Dermatology, Medical University of Vienna, Vienna, Austria
- 237 Spatial mapping of subcutaneous adipose tissue inflammation in panniculitis: Unveiling novel immune signatures**
Reihane Ziadlou^{1,2}, M.Milad Ameri^{1,2}, Marie-Charlotte Brüggem^{1,2}
¹University of Zürich, Zürich, Switzerland
²Department of Dermatology, University hospital of Zürich, Zürich, Switzerland
- 238 Epidermolysis Bullosa Pruriginosa : A case with albopapuloid lesions and elevated serum IgE**
Meryem Ayad¹, Samira Zobiri¹, Lynda Taibi¹, Dalila Bouharati¹, Aomar Ammar-Khodja¹
¹Hospital Mustapha Pacha, Algiers, Algeria

239 Severe Atopic Dermatitis is Associated with Increased Total Skin Bacterial Load Driven by Staphylococcus aureus Overgrowth

Avidan Uriel Neumann^{1,2}, Anna Reiter², Amadeo De Tomassi², Matthias Reiger², Luise Rauer^{1,2,3}, Robin Rohayem², Claudia Traidl-Hoffmann^{1,2,3,4,5}, Claudia Hülpüsch^{2,3,5}

¹*Institute of Environmental Medicine, Helmholtz Munich, Augsburg, Germany*

²*Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany*

³*Environmental Medicine, Technical University of Munich, Augsburg, Germany*

⁴*ZIEL—Institute for Food and Health, Technical University of Munich, Freising, Germany*

⁵*CK CARE, Christine-Kühne Center for Allergy Research and Education, Davos, Switzerland*

240 pH dependence of second immunoglobulin binding protein (Sbi) secretion by S aureus: Implications for atopic dermatitis immunopathogenesis

Qianxue Zhong¹, Yoyo Yeung¹, Helen Williams¹, Peter Arkwright¹, Joanne Pennock¹

¹*University Of Manchester, Manchester, United Kingdom*

241 Extraction bias and chimera formation predicted by bacterial morphology and cell number in microbiome sequencing data

Luise Rauer^{1,2,3}, Amadeo De Tomassi², Christian L. Müller^{4,5}, Claudia Hülpüsch^{2,6}, Claudia Traidl-Hoffmann^{1,2,3,6,7}, Matthias Reiger², Avidan Uriel Neumann^{1,2}

¹*Institute of Environmental Medicine, Helmholtz Munich, Augsburg, Germany*

²*Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany*

³*Chair of Environmental Medicine, Technical University of Munich, Munich, Germany*

⁴*Institute of Computational Biology, Helmholtz Munich, Neuherberg, Germany*

⁵*Department of Statistics, Ludwig-Maximilian University of Munich, Germany*

⁶*CK CARE, Christine Kühne Center for Allergy Research and Education, Davos, Switzerland*

⁷*ZIEL – Institute for Food & Health, Technical University of Munich, Freising, Germany*

242 Inhibition of STAT3/5 pathway by multi-kinase inhibitor IQDMA reduces tumor growth and outperforms conventional phototherapeutic treatment regime in cutaneous T cell lymphoma murine model.

Saptaswa Dey¹, Peter Wolf¹

¹*Department Of Dermatology, Medical University Of Graz, Graz, Austria*

243 TLR2/CD14 ligands from gram positive and gram negative bacteria inhibit IL-33 release from keratinocytes. Can diverse skin colonisation alone inhibit the allergic phenotype?

Helen Williams¹, Ryo Muko², Emily Wright¹, Reynard Spiess³, Hiroshi Matsuda², Akane Tanaka², Peter Arkwright¹, Joanne Pennock¹

¹*Lydia Becker Institute of Immunology and Inflammation, University Of Manchester, Manchester, United Kingdom*

²*Laboratories of Veterinary Molecular Pathology & Therapeutics and Comparative Animal Medicine, Tokyo University of Agriculture & Technology, Tokyo, Japan*



³*Manchester Institute of Biotechnology, University of Manchester, Manchester, United Kingdom*

244 Empowering Healthcare Professionals: Initial Findings from an Online Intervention for Pediatric Atopic Dermatitis in the Deep South of the United States

Thy Huynh¹, Manoj Sharma², Summer Morrisette¹, Jeremy Jackson¹, Robert Brodell¹, Vinayak Nahar¹

¹*University Of Mississippi Medical Center, Jackson, United States*

²*University of Nevada, Las Vegas, United States*

245 A Rare Case of Erythrodermic Sarcoidosis With Systemic Involvement After COVID-19 Vaccination

Brigit Lapolla¹, Emily Gordon², Oluwaseyi Adeuyan², Celine Schreidah², Lauren Fahmy², Cynthia Magro³, Larisa Geskin¹

¹*Department of Dermatology, Columbia University Irving Medical Center, New York, United States*

²*Columbia University Vagelos College of Physicians and Surgeons, New York, United States*

³*Division of Dermatopathology, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, United States*

246 Development of an Assessment Tool for Psychological Health and Help-Seeking in Alopecia Areata Patients in Underserved Communities

Thy Huynh¹, Manoj Sharma², Summer Morrisette¹, Jeremy Jackson¹, Robert Brodell¹, Vinayak Nahar¹

¹*University Of Mississippi Medical Center, Jackson, United States*

²*University of Nevada, Las Vegas, United States*

247 Efficacy of Probiotics X in Alleviating Clinical Severity and Anxiety/ Depressive-Like Behaviors in Mice with Atopic Dermatitis

Young Su Jang³, Jae-Sang Ryu¹, Hyeongjin Na², Hai Vin Kim³, Da Hye Seo³, Dong Hyun Kim¹, Jung U Shin¹

¹*Department of Dermatology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam-si, South Korea*

²*Department of Medicine, School of medicine, CHA University, Seongnam-si, South Korea*

³*Department of Biomedical Science, Graduate School, CHA University, Seongnam-si, South Korea*

248 Diagnosis and Treatment of Systemic Mastocytosis in Brazil: Recommendations of a Multidisciplinary Expert Panel

Georgia Padulla¹

¹*Private Office, São Paulo, Brazil*

- 249** Dermatoscopic Findings in Anal Pigment Lesion: Case Report
Georgia Padulla¹
¹*Private Office, São Paulo, Brazil*
- 250** A case of aggressive systemic mastocytosis with erythroderma showing response to midostaurin
Georgia Padulla¹, Pedro Giavina Bianchi²
¹*Private Office, São Paulo, Brazil*
²*Universidade de Sao Paulo, Sao Paulo, Brazil*
- 251** Aesthetic Procedures in a Patient with Rosacea
Georgia Padulla¹
¹*Private Office, São Paulo, Brazil*
- 252** Successful Management of Atopic Dermatitis with Phototherapy: A Case Report
Georgia Padulla¹
¹*Private Office, São Paulo, Brazil*
- 253** Frontal Fibrosing Alopecia: Clinical and Therapeutic Considerations - Case Series
Georgia Padulla¹
¹*Private Office, São Paulo, Brazil*
- 254** Cutaneous T-cell Lymphoma and Atopic Dermatitis: A Tale of Two Inflammatory Skin Conditions from a Single Cell RNA Sequencing Perspective
Oluwaseyi Adeuyan¹, Emily R. Gordon¹, Brigit A. Lapolla², Celine M. Schreidah¹, Lauren M. Fahmy¹, Caroline Chen¹, Larisa J. Geskin^{1,2}
¹*Columbia University Vagelos College Of Physicians And Surgeons, New York, United States*
²*Department of Dermatology, Columbia University Irving Medical Center, New York, United States*
- 255** Enhancing the Role of Ultrasound in Facial Mapping and Complementing with MRI in Patients with Injectable Fillers
Georgia Padulla¹
¹*Private Office, São Paulo, Brazil*



256 Case Study: Leprosy's Silent Emergence Amidst Diabetic Neuropathy Intricacies

Luana Moury Fernandes Sanchez¹, Ana Carolina Ventura de Santana de Jesus²,
Tatiane Alves Ferreira³, Maria Clara Galvao de Lima⁴, Larissa Alves Lourenco⁵,
Maria Eduarda Pires Albernaz⁶, Luiza Michalski Hentz⁷

¹Mount Sinai Hospital, New York, United States

²Bahiana Medical and Health School, Salvador, Brazil

³University 9th of July, Sao Paulo, Brazil

⁴University of Joao Pessoa- UNIPE, Joao Pessoa, PB

⁵University of Sao Francisco, Braganca, Brazil

⁶Federal University of Vale do Jequitinhonha e Mucuri, Diamantina, Brazil

⁷Lutheran University of Brazil, Canoas, Brazil

257 Immunophenotypic characterization of the cellular infiltrate associated with etiological factors in patients with atopic dermatitis

Sofia Victoria de los Santos Carmona¹, Brenda Hernández Rico¹, Elizabeth Ortega Rocha¹,
Catalina Rincón Pérez², Vadim Pérez Koldenkova³, Laura Bonifaz Alfonso¹

¹Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades, CMN Siglo XXI, IMSS, Mexico City, Mexico

²Servicio de Dermatología, Unidad de Especialidades Médicas, SEDENA, Mexico City, Mexico

³Laboratorio Nacional de Microscopía Avanzada, CMN Siglo XXI, IMSS, Mexico City, Mexico

258 Topical Disinfection Rebalances Impaired Cytokines in Polymorphic Light Eruption: Implications to Microbiota-Dependent Immune Modulation

Maximilian Zarfl¹, Vijaykumar Patra², Natalie Bordag¹, Franz Quehenberger³,
Nicole Golob-Schwarzl¹, Alexandra Gruber-Wackernagel¹, Peter Wolf^{1,4}

¹Medical University Of Graz, Departement Of Dermatology And Venereology, Research Unit for Photodermatology, Graz, Austria

²Centre International de Recherche en Infectiologie, Institut National de la Santé et de la Recherche Médicale, U1111, Université Claude Bernard Lyon, Lyon, France

³Medical University of Graz, Institute for Medical Informatics, Statistics and Documentation, Graz, Austria

⁴BioMedTech Graz, Graz, Austria

Late-breaking Abstracts

The following abstracts have been submitted after the regular abstract submission deadline and do not appear in the official abstract book.

- 259** **Single-cell profiling of over 500K activated PBMCs across 57 atopic dermatitis, psoriasis and age-sex matched healthy patient samples**
 Brian H Lee¹, Soyoun Jung¹, Junggho Lee¹, Christine Suh-Yun Joh¹, Gunwoo Park¹, Minji Kang¹, Hyojeong Nam, Hyun Seung Choi¹, Sowon Choi¹, Jiin Lee, Sojung Choi¹, Dong Jun Kim¹, Hyunje Kim^{2,3,4,5,6}
¹Seoul National University Graduate School Department of Biomedical Sciences, Seoul, South Korea
²Seoul National University Cancer Research Institute, Seoul, South Korea
³Seoul National University Department of Microbiology and Immunology, Seoul, South Korea
⁴Seoul National University Institute of Endemic Diseases, Seoul, South Korea
⁵Seoul National University Hospital, Seoul, South Korea,
⁶Seoul National University Genome Medicine Institute, South Korea
- 260** **The Phase 2 MIRA trial of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with active, moderate-to-severe hidradenitis suppurativa (HS): Week 12 results**
 Brian Kirby¹, James G. Krueger², Georgios Kokolakis³, Martina J. Porter⁴, Alexa B. Kimball⁴, Joslyn S. Kirby⁵, Nuala Brennan⁶, Alex Godwood⁶, Eva Cullen⁶, Kristian Reich^{6,7}, Andreas Pinter⁹
¹Charles Centre Department of Dermatology, St. Vincent's University Hospital and Charles Institute of Dermatology, University College Dublin, Dublin, Ireland
²Laboratory of Investigative Dermatology, The Rockefeller University, New York, USA
³Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, and Humboldt-Universität zu Berlin, Berlin, Germany
⁴Department of Dermatology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, USA
⁵Department of Dermatology, Penn State Health Dermatology, Hershey, USA
⁶MoonLake Immunotherapeutics AG, Zug, Switzerland
⁷Translational Research in Inflammatory Skin Diseases, Institute for Health Care Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
⁹Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Frankfurt, Germany



261 In-depth characterization of the inflammatory mechanisms underlying hidradenitis suppurativa (HS): Comparison of perilesional skin with nodules and tunnels

Eva Cullen¹, Ilaria Piccini², Markus Fehrholz², Sylke Schneider-Burrus^{3,4}, Brian Kirby⁵, Jean Fletcher^{6,7}, Marta Bertolini², Falk G. Bechara⁸, Kristian Reich^{1,9}, James G. Krueger¹⁰

¹*MoonLake Immunotherapeutics AG, Zug, Switzerland*

²*Monasterium Laboratory Skin & Hair Research Solutions, Münster, Germany*

³*Department of Immunology, University Hospital Charité, Berlin, Germany*

⁴*Centre for Dermatosurgery, Havelklinik, Berlin, Germany*

⁵*Charles Centre Department of Dermatology, St. Vincent's University Hospital and Charles Institute of Dermatology, University College Dublin, Dublin, Ireland*

⁶*School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland*

⁷*School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland*

⁸*Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany*

⁹*Translational Research in Inflammatory Skin Diseases, Institute for Health Care Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

¹⁰*Laboratory of Investigative Dermatology, The Rockefeller University, New York, USA*

262 Evidence of a role for IL-17F in the pathophysiology of dermal tunnels in hidradenitis suppurativa (HS): Implications for therapeutic interventions

Kristian Reich^{1,2}, Eva Cullen¹, Ilaria Piccini³, Onur Egriboz³, Sylke Schneider-Burrus^{4,5}, Brian Kirby⁶, Jean Fletcher^{7,8}, James G. Krueger⁹, Marta Bertolini³, Falk G. Bechara¹⁰

¹*MoonLake Immunotherapeutics AG, Zug, Switzerland*

²*Translational Research in Inflammatory Skin Diseases, Institute for Health Care Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

³*Monasterium Laboratory Skin & Hair Research Solutions, Münster, Germany*

⁴*Department of Immunology, University Hospital Charité, Berlin, Germany*

⁵*Center for Dermatosurgery, Havelklinik, Berlin, Germany*

⁶*Charles Centre Department of Dermatology, St. Vincent's University Hospital and Charles Institute of Dermatology, University College Dublin, Dublin, Ireland*

⁷*School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland*

⁸*School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland*

⁹*Laboratory of Investigative Dermatology, The Rockefeller University, New York, USA*

¹⁰*Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany*

- 263 Multi-omics Analysis of microbiome and tryptophan metabolites by skin region of atopic dermatitis in child**
Han Bi Kim¹, Ji Young Um¹, Jin Cheol Kim¹, Bo Young Chung¹, Chun Wook Park¹, Kwon eel Kim², Hye one Kim¹
¹Department Of Dermatology, Hallym Univ. Kangnam Sacred Heart Hospital, Seoul, South Korea
²Department of Biomedical and Pharmaceutical Sciences, Kyung Hee University, Seoul, South Korea
- 264 Evaluating the Use of Dual Biologics in Inflammatory and Autoimmune Disease**
M. Grace Hren¹, Sophie Guenin², Saakshi Khattri¹
¹Icahn School of Medicine at Mount Sinai, New York, United States
- 265 First-in-human results from a phase 1 single- and multiple-ascending dose study in healthy participants assessing the safety, pharmacokinetics, and pharmacodynamics of the interleukin-17A inhibitor JNJ-81241459**
 Irving Ling¹, Monica Leung¹, Alexa Piantone¹, Vikash Sinha¹, Dawei Song¹, Brian Scott¹, Meghan Pryor¹, Katrien Verbruggen¹, David La¹, Ilia Tikhonov¹, Koen Ceulemans¹, Sharan Nischal¹, Marta Polak¹, Patrick Eidam¹, Steven Goldberg¹, Rajesh Rao¹, Ya-Wen Yang²
¹Janssen Research & Development, LLC, United States
²Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, United States
- 266 Autoreactive IgE antibodies in atopic dermatitis are linked with Type-2 comorbidities and the atopic march**
 Inge Kortekaas Krohn^{1,2}, Fariza Mishaal Saiema Badloe^{1,2}, Nadine Herrmann^{3,4}, Laura Maintz^{3,4}, Johannes Ring⁵, CK-CARE study group⁴, Thomas Bieber^{3,4,6}, Jan Gutermuth^{1,2}
¹Vrije Universiteit Brussel (VUB), Skin Immunology & Immune Tolerance (SKIN) Research Group, Brussels, Belgium
²Department of Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel, Brussels, Belgium
³Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany
⁴Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland
⁵Department Dermatology and Allergy Biederstein, Technical University Munich, Munich, Germany
⁶Davos Biosciences, Davos, Switzerland
- 267 The dependence of phototherapy treatment survival rates on subtypes of psoriasis and availability of alternative treatment options**
 Thomas Graier¹, Angelika Hofer¹, Wolfgang Weger¹, Alexandra Gruber-Wackernagel¹, Franz Legat¹, A Widnig¹, Katharina Falkensteiner¹, Wolfgang Salmhofer¹, Natalie Bordag¹, Peter Wolf¹
¹Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria



- 268** **Teledermatology in Styria connecting general practitioners to dermatologists: a practical triage system**
Natalie Bordag¹, Elena Hofmann-Wellenhof, Rainer Hofmann-Wellenhof, Edith Arzberger
¹*Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria*
- 269** **Neutrophilic Urticaria Following Semaglutide Use**
Akber Sheikh^{1,2}, Dale Macknet^{2,3}, Cathy Macknet^{2,3}, Maria Isales²
¹*Western University Of Health Sciences, Pomona, United States*
²*California Skin Institute, Loma Linda, United States*
³*Department of Dermatology, Loma Linda University School of Medicine, Loma Linda, United States*
- 270** **Melanoma Home Treatment with Frankincense Prior to Excisional Surgery**
Akber Sheikh^{1,2}, Lavonne Meadows^{2,3}
¹*Western University Of Health Sciences, Pomona, United States*
²*California Skin Institute, Loma Linda, United States*
³*Department of Dermatology, Loma Linda University School of Medicine, Loma Linda, United States*
- 271** **Unique Presentation of Blastic Plasmacytoid Dendritic Cells Neoplasm**
Akber Sheikh^{1,2}, Chelsea Huang²
¹*Western University Of Health Sciences, Pomona, United States*
²*Department of Dermatology, Loma Linda University School of Medicine, Loma Linda, United States*
- 272** **Unique Presentation of Endocrine Mucin-Producing Sweat Gland Carcinoma**
Akber Sheikh^{1,2}, Chelsea Huang²
¹*Western University Of Health Sciences, Pomona, United States*
²*Department of Dermatology, Loma Linda University School of Medicine, Loma Linda, United States*
- 273** **Erythrodermic Psoriasis Successfully Treated with Secukinumab: A Case Report**
Holy Ametati¹, Rahmat Sugianto, Nur Zulfa
¹*Kariadi Hospital, Semarang, Indonesia*
- 274** **Toxic Epidermal Necrolysis Preceded by Chronic Dermatitis Seborrheic in A 13-year-old Female**
Holy Ametati¹, Felicia Afrilia
¹*Kariadi Hospital, Semarang, Indonesia*

- 275 ERYTHRODERMIC BULLOUS PEMPHIGOID WITH NORWEGIAN SCABIES : A RARE CASE REPORT**
Holy Ametat¹, Diah Malik, Renni Yuniati, Medisiana Soenoe
¹Kariadi Hospital, Semarang, Indonesia
- 276 Novel targeted phototherapies for the treatment of CTCL and other inflammatory skin diseases**
Eric Kercher^{1,2}, Amissi Sadiki¹, Kingsely Essien^{1,2}, Shanshan Liu¹, John Harris^{1,2}
¹Nira Biosciences, Burlington, United States
²UMass Chan Medical School, Worcester, United States
- 277 Efficacy, Safety, and Tolerability of GSK1070806, an Anti-IL-18 Monoclonal Antibody, in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study**
John Kelly¹, Joanne Ellis², Lea Fortunata², Núria Buil-Bruna², Joanna Barnard², Jenny Lowe³, Simon Safa-Leathers², Scott Dinehart⁴, Gabriel Wong², Iain Uings²
¹GSK, Collegetown, United States
²GSK, Stevenage, United Kingdom
³GSK, London, United Kingdom
⁴Arkansas Dermatology, Little Rock, United States
- 278 Spesolimab treatment controls GPP disease characteristics in acute and chronic phases**
Sudha Visvanathan¹, Ahmed Farag², Akimichi Morita³, Mark G. Lebwohl⁴, Richard B. Warren⁵, A. David Burden⁶, Denis Delic⁷, Kolja Becker⁷, Christian Thoma², James G. Krueger⁸
¹Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, United States
²Boehringer Ingelheim International GmbH, Ingelheim Am Rhein, Germany
³Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
⁴Icahn School of Medicine at Mount Sinai, New York, USA
⁵Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Salford Royal, Salford, UK
⁶School of Infection and Immunity, University of Glasgow, Glasgow, UK
⁷Boehringer Ingelheim International GmbH, Biberach, Germany
⁸Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA
- 279 Deciphering the pathophysiological pathways in atopic dermatitis using a multi-omics approach**
Lina Gross¹, Alexandra Wallimann, Erik Kupschke, Mirjam Schenk
¹CK-CARE, Davos, Schweiz



Sponsors & Exhibitors

Platinum Level Sponsorship



Gold Level Sponsorship

Boehringer Ingelheim
UCB

Silver Level Sponsorship

Dermavant Sciences, Inc.
Incyte
Leo Pharma

Bronze Level Sponsorship

AnaptysBio
Apogee Therapeutics
Arcutis Biotherapeutics
Kyowa Kirin GmbH
SCARLETRED Holding GmbH

CTCL Sponsorship

Kyowa Kirin GmbH

Industry Supported Sessions

Complimentary Non-CME Symposia

WEDNESDAY, NOVEMBER 15, 2023

12.00 PM - 01.00 PM Lunch Symposium by Kyowa Kirin

THURSDAY, NOVEMBER 16, 2023

08.00 AM - 09:30 AM Breakfast Symposium by Sanofi and Regeneron

12.00 PM - 01.30 PM Lunch Symposium by Janssen

FRIDAY, NOVEMBER 17, 2023

12.00 PM - 01.30 PM Lunch Symposium by Eli Lilly and Almirall

07.00 PM - 08.30 PM Dinner Symposium by Bristol Myers Squibb

SATURDAY, NOVEMBER 18, 2023

12.15 PM - 01.45 PM Lunch Symposium by Pfizer

03.30 PM - 06.00 PM Industry Satellite Event by Bristol Myers Squibb



5. ISDS INFLAMMATORY SKIN DISEASE SUMMIT

HOW TO MANAGE MF AND SS?

Wed 15th Nov | 12:00 – 13:00 | Aula der Wissenschaften | Vienna, Austria

5 min	Greeting and Introduction, Audience Questions <i>Chair: Assoc. Prof. Constanze Jonak, Vienna</i>
15 min	New and combination therapies – dreams of the future? <i>Assoc. Prof. Constanze Jonak, Vienna</i>
15 min	Update on Mogamulizumab in MF and SS – MAVORIC vs. Real world evidence <i>Prof. Patrick Brunner, NY</i>
15 min	Progression vs. Mogamulizumab associated rash (MAR) – pitfalls and opportunities under Mogamulizumab Therapy <i>Dr. Gabor Dobos, Berlin</i>
10 min	General Discussion



Navigating Recent Scientific Advances in Atopic Dermatitis

Thursday, 16 November 2023 / 08:00–09:30 CET
Vienna, Austria / Aula der Wissenschaften


FACULTY



Lisa Beck, MD
University of Rochester
Medical Center, USA



Robert Bissonnette, MD
Innovaderm Research Inc.,
Canada



Gil Yosipovitch, MD
University of Miami,
USA

LEARNING OBJECTIVES

- Review the latest evidence on how type 2 inflammation drives skin barrier dysfunction in atopic dermatitis
- Discuss the evidence illustrating how type 2 inflammation affects the skin microbiome in atopic dermatitis
- Explore the impact of type 2 inflammation in neuroimmune axis dysregulation in atopic dermatitis



ADVENT is an award-winning medical education program developed by

sanofi | **REGENERON**[®]

Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch



Join us for an ADVENT-sponsored symposium
at **ISDS 2023!**

AGENDA

Introduction

Lisa Beck (Chair)

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

Robert Bissonnette

Skin Dysbiosis in AD

Lisa Beck

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

Gil Yosipovitch

Panel discussion and Q&A

All Faculty

Developed with clinical experts to advance the understanding of type 2 inflammation

Janssen-Sponsored Satellite Symposium at the ISDS Congress 2023

Translating research into patient management: can we modify psoriatic disease?

Thursday 16 November 2023 | 12:00–13:30 (CET)

Aula der Wissenschaften, Vienna, Austria

Faculty



Robert Bissonnette
(Canada)



Liv Eidsmo
(Denmark)



James Krueger
(United States)



Peter Wolf
(Austria)

Join us for the Janssen-sponsored satellite symposium at the ISDS Congress 2023. Hear from the experts in a series of interactive discussions as they explore topics such as the discovery of IL-23, the role of TRM cells, the benefits of early intervention, and what the future holds for psoriatic disease treatments. We invite you to actively participate in engaging Q&A sessions and deepen your insights into the latest updates on psoriasis treatment from both molecular and clinical standpoints.

Congress registration is required.
This session is for healthcare professionals (HCPs) only.
A lunch box will be provided prior to this symposium.



Scan the QR code
to leave your
feedback

Learning objectives

After this symposium, participants should be able to:

- Identify the pathophysiological mechanisms driving psoriasis and psoriatic arthritis (PsA) inflammation and disease progression
- Discuss recent mechanistic and clinical data on tissue-resident memory cells, IL-23 pathway inhibition, and the benefits of early intervention
- Differentiate therapies for psoriasis and PsA based on mechanisms of action, molecular profile, efficacy, and safety data

Programme

- 12:00–12:05 **Welcome and introduction**
Peter Wolf (moderator/interviewer in all sessions)
- 12:05–12:20 **Behind the scenes: molecular mechanisms in psoriatic disease**
Liv Eidsmo
- 12:20–12:25 **Q&A session**
All speakers
- 12:25–12:50 **The evolving journey: disease memory and molecular differentiation**
Robert Bissonnette and James Krueger
- 12:50–12:55 **Q&A session**
All speakers
- 12:55–13:15 **What is on the horizon: updates on the management of psoriasis**
Robert Bissonnette and Liv Eidsmo
- 13:15–13:30 **Patient care: putting it all into practice**
Q&A session, panel discussion, and closing remarks
All speakers

Hitting the Bull's Eye: Selective Targeting in Atopic Dermatitis

Friday, 17th November 2023 | 12:00–13:30 CET

Main Auditorium, Aula der Wissenschaften, Wollzeile 27a, A-1010
Vienna, Austria

IN-PERSON 

ACTIVITY OVERVIEW

International experts will engage in a fast-paced round robin Q&A about hot topics in IL-13 as related to atopic dermatitis. This will be followed by a review of the evolving story of type 2 immunity from a historical perspective, from discovery through to current understanding. Experts will then provide updates on IL-13 in non-lesional and lesional skin and ethnic, racial, and age similarities with respect to IL-13. The final presentation will discuss the latest science regarding mechanisms of IL-13 inhibition, mechanisms of action of approved and forthcoming IL-13 targeting drugs, and properties and attributes of each molecule.

TOPLINE AGENDA

Welcome and Introductions

Expert Quickfire

The Evolving Story of Type 2 Immunity


Updates on IL-13: The Key Cytokine in AD

What's New Regarding Mechanisms of IL-13 Inhibition?

Panel Discussion

Concluding Remarks/Final Thoughts





CHAIR



Emma Guttman, MD, PhD

Waldman Professor and Health System Chair
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York, United States

SPEAKERS



Patrick M. Brunner, MD

Associate Professor of Dermatology
Director of the Cutaneous Lymphoma Clinic
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York, United States



Alan D. Irvine, MD

Professor of Dermatology
Trinity College Dublin
Dublin, Ireland

LEARNING OBJECTIVES

- Improve understanding of the role of IL-13 targeting in atopic dermatitis
- Describe various mechanisms of targeting IL-13 and the impact of each

Psoriatic Disease Update:

A Deep Dive Into Unmet Needs, Systemic Inflammation, and Oral Targeted Therapies


November 17th, 2023 | 19:00-20:30
Main Auditorium - Aula der Wissenschaften



Chair

Georg Stingl, MD

Medical University of Vienna
Austria



Disease Burden and Unmet Needs in Psoriasis: Lessons From Real-World Data

Joseph F. Merola, MD, MMSc

UT Southwestern Medical Center

United States



Systemic Inflammation and Comorbidities in Patients With Psoriasis

Alice B. Gottlieb, MD, PhD

Mount Sinai Beth Israel Dermatology,
Icahn School of Medicine at Mount Sinai

United States



The Cardiovascular Risk Factors, Patient Management and Role of the Dermatologist as Part of the Multidisciplinary Approach

Álvaro González-Cantero, MD, PhD

Ramón y Cajal University Hospital

Spain



Oral Therapeutic Landscape in Psoriasis: The New Class of Targeted TYK2 Inhibitors

Constanze Jonak, MD

Medical University of Vienna

Austria



HOW ARE NOVEL TREATMENT TARGETS CHANGING THE THERAPEUTIC LANDSCAPE IN IMMUNO-INFLAMMATORY DISEASES?

Join Pfizer for a lunch symposium at ISDS
to explore this question and more on

From Bench to Bedside: The Changing Therapeutic Landscape of Alopecia Areata and Vitiligo


 Saturday, November 18, 2023
12.15 PM – 01.45 PM CET

 Jesuitensaal Lecture Hall,
Aula Der Wissenschaften,
Vienna, Austria

**We look forward
to seeing you there!**



Derm is a medical education program being developed for healthcare professionals only and is organized by Pfizer. Pfizer Corporation Austria GmbH · Floridsdorfer Hauptstraße 1, 1210 Wien
www.pfizer.at, E-Mail: pfizer.austria@pfizer.com, Tel: +43 1 521 15 0
PP-UNP-GLB-1698 ©2023 Pfizer Inc. All rights reserved. October 2023.



Transforming patient health by delivering innovative immunology therapeutics

Find out more at www.anaptysbio.com

AnaptysBio



LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,700 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.





www.isds2023.org



5th Inflammatory Skin Disease Summit 2023